EP1434596B1 - Amelioration des reponses immunitaires par des anticorps agonistes liant 4-1bb - Google Patents
Amelioration des reponses immunitaires par des anticorps agonistes liant 4-1bb Download PDFInfo
- Publication number
- EP1434596B1 EP1434596B1 EP02802551A EP02802551A EP1434596B1 EP 1434596 B1 EP1434596 B1 EP 1434596B1 EP 02802551 A EP02802551 A EP 02802551A EP 02802551 A EP02802551 A EP 02802551A EP 1434596 B1 EP1434596 B1 EP 1434596B1
- Authority
- EP
- European Patent Office
- Prior art keywords
- cell
- antigen
- cells
- peptide
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 230000028993 immune response Effects 0.000 title claims abstract description 21
- 239000000556 agonist Substances 0.000 title description 3
- 210000001744 T-lymphocyte Anatomy 0.000 claims abstract description 177
- 238000000034 method Methods 0.000 claims abstract description 90
- 238000000338 in vitro Methods 0.000 claims abstract description 35
- 230000004044 response Effects 0.000 claims abstract description 26
- 230000006698 induction Effects 0.000 claims abstract description 22
- 210000004027 cell Anatomy 0.000 claims description 280
- 206010028980 Neoplasm Diseases 0.000 claims description 152
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 149
- 108091007433 antigens Proteins 0.000 claims description 133
- 102000036639 antigens Human genes 0.000 claims description 133
- 239000000427 antigen Substances 0.000 claims description 132
- 230000001270 agonistic effect Effects 0.000 claims description 77
- 210000004881 tumor cell Anatomy 0.000 claims description 68
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 108091008874 T cell receptors Proteins 0.000 claims description 45
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims description 45
- 108020004707 nucleic acids Proteins 0.000 claims description 43
- 102000039446 nucleic acids Human genes 0.000 claims description 43
- 150000007523 nucleic acids Chemical class 0.000 claims description 43
- 210000004443 dendritic cell Anatomy 0.000 claims description 41
- 206010011968 Decreased immune responsiveness Diseases 0.000 claims description 36
- 229920001184 polypeptide Polymers 0.000 claims description 33
- 108700018351 Major Histocompatibility Complex Proteins 0.000 claims description 32
- 239000012634 fragment Substances 0.000 claims description 32
- 230000020382 suppression by virus of host antigen processing and presentation of peptide antigen via MHC class I Effects 0.000 claims description 32
- 208000015181 infectious disease Diseases 0.000 claims description 27
- 244000005700 microbiome Species 0.000 claims description 25
- 230000002458 infectious effect Effects 0.000 claims description 23
- 108090000623 proteins and genes Proteins 0.000 claims description 22
- 201000011510 cancer Diseases 0.000 claims description 20
- 102000004169 proteins and genes Human genes 0.000 claims description 19
- 102000004127 Cytokines Human genes 0.000 claims description 15
- 108090000695 Cytokines Proteins 0.000 claims description 15
- 108010004889 Heat-Shock Proteins Proteins 0.000 claims description 15
- 102000002812 Heat-Shock Proteins Human genes 0.000 claims description 15
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 14
- 201000001441 melanoma Diseases 0.000 claims description 14
- 241000700605 Viruses Species 0.000 claims description 13
- 210000004754 hybrid cell Anatomy 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000013592 cell lysate Substances 0.000 claims description 8
- 238000012258 culturing Methods 0.000 claims description 8
- 241000894006 Bacteria Species 0.000 claims description 7
- 102000008949 Histocompatibility Antigens Class I Human genes 0.000 claims description 7
- 102000018713 Histocompatibility Antigens Class II Human genes 0.000 claims description 7
- 206010025323 Lymphomas Diseases 0.000 claims description 7
- 230000005867 T cell response Effects 0.000 claims description 7
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 6
- 230000003213 activating effect Effects 0.000 claims description 6
- 239000003102 growth factor Substances 0.000 claims description 6
- 201000005202 lung cancer Diseases 0.000 claims description 6
- 208000020816 lung neoplasm Diseases 0.000 claims description 6
- 208000018084 Bone neoplasm Diseases 0.000 claims description 5
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 108010088652 Histocompatibility Antigens Class I Proteins 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 206010060862 Prostate cancer Diseases 0.000 claims description 5
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 5
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 5
- 230000004927 fusion Effects 0.000 claims description 5
- 201000010536 head and neck cancer Diseases 0.000 claims description 5
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 5
- 208000032839 leukemia Diseases 0.000 claims description 5
- 201000007270 liver cancer Diseases 0.000 claims description 5
- 208000014018 liver neoplasm Diseases 0.000 claims description 5
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 5
- 230000000926 neurological effect Effects 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 5
- 244000000040 protozoan parasite Species 0.000 claims description 5
- 208000015347 renal cell adenocarcinoma Diseases 0.000 claims description 5
- 238000010361 transduction Methods 0.000 claims description 5
- 230000026683 transduction Effects 0.000 claims description 5
- 206010005949 Bone cancer Diseases 0.000 claims description 4
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 claims description 4
- 108010027412 Histocompatibility Antigens Class II Proteins 0.000 claims description 4
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 claims description 4
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 claims description 4
- 241000124008 Mammalia Species 0.000 claims description 4
- 208000008385 Urogenital Neoplasms Diseases 0.000 claims description 4
- 238000001890 transfection Methods 0.000 claims description 4
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 201000011531 vascular cancer Diseases 0.000 claims description 4
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims 6
- 230000002708 enhancing effect Effects 0.000 abstract description 6
- 241000699670 Mus sp. Species 0.000 description 213
- 241000700159 Rattus Species 0.000 description 66
- 230000002163 immunogen Effects 0.000 description 58
- 239000011230 binding agent Substances 0.000 description 51
- 238000011282 treatment Methods 0.000 description 41
- 230000000694 effects Effects 0.000 description 30
- 210000000612 antigen-presenting cell Anatomy 0.000 description 29
- 241000699666 Mus <mouse, genus> Species 0.000 description 28
- 210000001165 lymph node Anatomy 0.000 description 24
- 238000002347 injection Methods 0.000 description 22
- 239000007924 injection Substances 0.000 description 22
- 238000002474 experimental method Methods 0.000 description 21
- 230000003053 immunization Effects 0.000 description 20
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 19
- 238000002649 immunization Methods 0.000 description 19
- 239000002953 phosphate buffered saline Substances 0.000 description 19
- 238000003556 assay Methods 0.000 description 17
- 238000007920 subcutaneous administration Methods 0.000 description 17
- 101800001318 Capsid protein VP4 Proteins 0.000 description 16
- 241001529936 Murinae Species 0.000 description 16
- 235000018102 proteins Nutrition 0.000 description 16
- 230000009261 transgenic effect Effects 0.000 description 16
- 230000000890 antigenic effect Effects 0.000 description 15
- 230000004083 survival effect Effects 0.000 description 15
- 238000012360 testing method Methods 0.000 description 15
- 230000017274 T cell anergy Effects 0.000 description 13
- 210000004698 lymphocyte Anatomy 0.000 description 13
- 230000035755 proliferation Effects 0.000 description 13
- 210000000952 spleen Anatomy 0.000 description 13
- 210000004989 spleen cell Anatomy 0.000 description 13
- 230000011664 signaling Effects 0.000 description 12
- 238000010186 staining Methods 0.000 description 12
- 108010002350 Interleukin-2 Proteins 0.000 description 10
- 102000000588 Interleukin-2 Human genes 0.000 description 10
- 239000012636 effector Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 9
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 9
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 9
- 239000013604 expression vector Substances 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 8
- 108010074328 Interferon-gamma Proteins 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 8
- 210000004408 hybridoma Anatomy 0.000 description 8
- 238000011830 transgenic mouse model Methods 0.000 description 8
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 7
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 7
- 239000000816 peptidomimetic Substances 0.000 description 7
- 102000002627 4-1BB Ligand Human genes 0.000 description 6
- 108010082808 4-1BB Ligand Proteins 0.000 description 6
- 210000001266 CD8-positive T-lymphocyte Anatomy 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- 108091054437 MHC class I family Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 6
- 230000000139 costimulatory effect Effects 0.000 description 6
- 230000003013 cytotoxicity Effects 0.000 description 6
- 231100000135 cytotoxicity Toxicity 0.000 description 6
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- LKKMLIBUAXYLOY-UHFFFAOYSA-N 3-Amino-1-methyl-5H-pyrido[4,3-b]indole Chemical compound N1C2=CC=CC=C2C2=C1C=C(N)N=C2C LKKMLIBUAXYLOY-UHFFFAOYSA-N 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 5
- 238000011765 DBA/2 mouse Methods 0.000 description 5
- 102100037850 Interferon gamma Human genes 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108010076504 Protein Sorting Signals Proteins 0.000 description 5
- 230000006052 T cell proliferation Effects 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 239000002671 adjuvant Substances 0.000 description 5
- 230000000961 alloantigen Effects 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 238000013459 approach Methods 0.000 description 5
- 239000002299 complementary DNA Substances 0.000 description 5
- 239000012091 fetal bovine serum Substances 0.000 description 5
- 108020001507 fusion proteins Proteins 0.000 description 5
- 102000037865 fusion proteins Human genes 0.000 description 5
- 238000010348 incorporation Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 230000001717 pathogenic effect Effects 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 230000002441 reversible effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 4
- 241000341655 Human papillomavirus type 16 Species 0.000 description 4
- 102000043129 MHC class I family Human genes 0.000 description 4
- 108091054438 MHC class II family Proteins 0.000 description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000009089 cytolysis Effects 0.000 description 4
- 230000001461 cytolytic effect Effects 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 210000002443 helper t lymphocyte Anatomy 0.000 description 4
- 238000011081 inoculation Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 210000001616 monocyte Anatomy 0.000 description 4
- 229920001778 nylon Polymers 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 210000004988 splenocyte Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 241000283707 Capra Species 0.000 description 3
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 3
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 3
- 102000008070 Interferon-gamma Human genes 0.000 description 3
- 102000004388 Interleukin-4 Human genes 0.000 description 3
- 108090000978 Interleukin-4 Proteins 0.000 description 3
- 206010027458 Metastases to lung Diseases 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 239000004365 Protease Substances 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 108020004511 Recombinant DNA Proteins 0.000 description 3
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000002981 blocking agent Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000000981 bystander Effects 0.000 description 3
- 230000016396 cytokine production Effects 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- -1 e.g. Proteins 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 239000012678 infectious agent Substances 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 229940028885 interleukin-4 Drugs 0.000 description 3
- 210000002540 macrophage Anatomy 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 230000003442 weekly effect Effects 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 241000589969 Borreliella burgdorferi Species 0.000 description 2
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 241000701489 Cauliflower mosaic virus Species 0.000 description 2
- 108010058432 Chaperonin 60 Proteins 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- 101150013359 E7 gene Proteins 0.000 description 2
- 108010008655 Epstein-Barr Virus Nuclear Antigens Proteins 0.000 description 2
- 101000609762 Gallus gallus Ovalbumin Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 239000012981 Hank's balanced salt solution Substances 0.000 description 2
- 241000725303 Human immunodeficiency virus Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- 101000767631 Human papillomavirus type 16 Protein E7 Proteins 0.000 description 2
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 2
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 2
- 108010065805 Interleukin-12 Proteins 0.000 description 2
- 102000013462 Interleukin-12 Human genes 0.000 description 2
- 101710125418 Major capsid protein Proteins 0.000 description 2
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 2
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 2
- 206010027476 Metastases Diseases 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- 241000588650 Neisseria meningitidis Species 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 206010035226 Plasma cell myeloma Diseases 0.000 description 2
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 229920002684 Sepharose Polymers 0.000 description 2
- 240000002825 Solanum vestissimum Species 0.000 description 2
- 235000018259 Solanum vestissimum Nutrition 0.000 description 2
- 206010042971 T-cell lymphoma Diseases 0.000 description 2
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 2
- 241000723873 Tobacco mosaic virus Species 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 241000607447 Yersinia enterocolitica Species 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 229940024606 amino acid Drugs 0.000 description 2
- 230000005875 antibody response Effects 0.000 description 2
- 210000000988 bone and bone Anatomy 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229940038705 chlamydia trachomatis Drugs 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229940029030 dendritic cell vaccine Drugs 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 231100000655 enterotoxin Toxicity 0.000 description 2
- 208000010932 epithelial neoplasm Diseases 0.000 description 2
- 230000003325 follicular Effects 0.000 description 2
- 102000054766 genetic haplotypes Human genes 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 210000004524 haematopoietic cell Anatomy 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001506 immunosuppresive effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000004073 interleukin-2 production Effects 0.000 description 2
- 239000003446 ligand Substances 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 229920002521 macromolecule Polymers 0.000 description 2
- 108700025647 major vault Proteins 0.000 description 2
- 201000006512 mast cell neoplasm Diseases 0.000 description 2
- 208000006971 mastocytoma Diseases 0.000 description 2
- 239000011325 microbead Substances 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 108700042226 ras Genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000003393 splenic effect Effects 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 230000002103 transcriptional effect Effects 0.000 description 2
- 230000002463 transducing effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 201000008827 tuberculosis Diseases 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- JVJGCCBAOOWGEO-RUTPOYCXSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-4-amino-2-[[(2s,3s)-2-[[(2s,3s)-2-[[(2s)-2-azaniumyl-3-hydroxypropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoyl]amino]-4-oxobutanoyl]amino]-3-phenylpropanoyl]amino]-4-carboxylatobutanoyl]amino]-6-azaniumy Chemical compound OC[C@H](N)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(O)=O)CC1=CC=CC=C1 JVJGCCBAOOWGEO-RUTPOYCXSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- GZCWLCBFPRFLKL-UHFFFAOYSA-N 1-prop-2-ynoxypropan-2-ol Chemical compound CC(O)COCC#C GZCWLCBFPRFLKL-UHFFFAOYSA-N 0.000 description 1
- WEEMDRWIKYCTQM-UHFFFAOYSA-N 2,6-dimethoxybenzenecarbothioamide Chemical compound COC1=CC=CC(OC)=C1C(N)=S WEEMDRWIKYCTQM-UHFFFAOYSA-N 0.000 description 1
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- OSJPPGNTCRNQQC-UWTATZPHSA-N 3-phospho-D-glyceric acid Chemical compound OC(=O)[C@H](O)COP(O)(O)=O OSJPPGNTCRNQQC-UWTATZPHSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- 102100038222 60 kDa heat shock protein, mitochondrial Human genes 0.000 description 1
- 102000013563 Acid Phosphatase Human genes 0.000 description 1
- 108010051457 Acid Phosphatase Proteins 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 108700031308 Antennapedia Homeodomain Proteins 0.000 description 1
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 1
- 240000005528 Arctium lappa Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 102100035526 B melanoma antigen 1 Human genes 0.000 description 1
- 235000014469 Bacillus subtilis Nutrition 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108700031361 Brachyury Proteins 0.000 description 1
- 101100124795 Caenorhabditis elegans hsp-110 gene Proteins 0.000 description 1
- 102100029968 Calreticulin Human genes 0.000 description 1
- 108090000549 Calreticulin Proteins 0.000 description 1
- 241000222122 Candida albicans Species 0.000 description 1
- 101710132601 Capsid protein Proteins 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- GXGJIOMUZAGVEH-UHFFFAOYSA-N Chamazulene Chemical group CCC1=CC=C(C)C2=CC=C(C)C2=C1 GXGJIOMUZAGVEH-UHFFFAOYSA-N 0.000 description 1
- 102000006303 Chaperonin 60 Human genes 0.000 description 1
- 101710094648 Coat protein Proteins 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 101100125027 Dictyostelium discoideum mhsp70 gene Proteins 0.000 description 1
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000224432 Entamoeba histolytica Species 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- OTMSDBZUPAUEDD-UHFFFAOYSA-N Ethane Chemical compound CC OTMSDBZUPAUEDD-UHFFFAOYSA-N 0.000 description 1
- 208000001382 Experimental Melanoma Diseases 0.000 description 1
- 241000713800 Feline immunodeficiency virus Species 0.000 description 1
- 241000714165 Feline leukemia virus Species 0.000 description 1
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 1
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 1
- 101710177917 Fimbrial protein Proteins 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102100021181 Golgi phosphoprotein 3 Human genes 0.000 description 1
- 101150031823 HSP70 gene Proteins 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 241000228404 Histoplasma capsulatum Species 0.000 description 1
- 101000971171 Homo sapiens Apoptosis regulator Bcl-2 Proteins 0.000 description 1
- 101000874316 Homo sapiens B melanoma antigen 1 Proteins 0.000 description 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 1
- 101000946843 Homo sapiens T-cell surface glycoprotein CD8 alpha chain Proteins 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 101100156155 Human papillomavirus type 16 E7 gene Proteins 0.000 description 1
- 101000954493 Human papillomavirus type 16 Protein E6 Proteins 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 102100020755 Hypoxia up-regulated protein 1 Human genes 0.000 description 1
- 108700002232 Immediate-Early Genes Proteins 0.000 description 1
- 108010008212 Integrin alpha4beta1 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- 102000000646 Interleukin-3 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010002586 Interleukin-7 Proteins 0.000 description 1
- 102000000704 Interleukin-7 Human genes 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241000222732 Leishmania major Species 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000186779 Listeria monocytogenes Species 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 208000032271 Malignant tumor of penis Diseases 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010027480 Metastatic malignant melanoma Diseases 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 102100034263 Mucin-2 Human genes 0.000 description 1
- 108010008705 Mucin-2 Proteins 0.000 description 1
- 241000186362 Mycobacterium leprae Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- BKAYIFDRRZZKNF-VIFPVBQESA-N N-acetylcarnosine Chemical compound CC(=O)NCCC(=O)N[C@H](C(O)=O)CC1=CN=CN1 BKAYIFDRRZZKNF-VIFPVBQESA-N 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 101710141454 Nucleoprotein Proteins 0.000 description 1
- 101710203389 Outer membrane porin F Proteins 0.000 description 1
- 101710116435 Outer membrane protein Proteins 0.000 description 1
- 101710160104 Outer membrane protein F Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 102000036673 PRAME Human genes 0.000 description 1
- 108060006580 PRAME Proteins 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 206010034299 Penile cancer Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 241000235648 Pichia Species 0.000 description 1
- 241000223960 Plasmodium falciparum Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000605862 Porphyromonas gingivalis Species 0.000 description 1
- 241000347168 Porphyromonas gingivalis 381 Species 0.000 description 1
- 101710083689 Probable capsid protein Proteins 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- ODHCTXKNWHHXJC-GSVOUGTGSA-N Pyroglutamic acid Natural products OC(=O)[C@H]1CCC(=O)N1 ODHCTXKNWHHXJC-GSVOUGTGSA-N 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 241000235070 Saccharomyces Species 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 241000713311 Simian immunodeficiency virus Species 0.000 description 1
- 206010041660 Splenomegaly Diseases 0.000 description 1
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 230000006044 T cell activation Effects 0.000 description 1
- 230000020385 T cell costimulation Effects 0.000 description 1
- 102100034922 T-cell surface glycoprotein CD8 alpha chain Human genes 0.000 description 1
- 101710192266 Tegument protein VP22 Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 241000710209 Theiler's encephalomyelitis virus Species 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 108700019146 Transgenes Proteins 0.000 description 1
- 102000003425 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- ODHCTXKNWHHXJC-UHFFFAOYSA-N acide pyroglutamique Natural products OC(=O)C1CCC(=O)N1 ODHCTXKNWHHXJC-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000002001 anti-metastasis Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000005809 anti-tumor immunity Effects 0.000 description 1
- 230000007503 antigenic stimulation Effects 0.000 description 1
- 230000005975 antitumor immune response Effects 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000000637 arginyl group Chemical group N[C@@H](CCCNC(N)=N)C(=O)* 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001540 azides Chemical class 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000035584 blastogenesis Effects 0.000 description 1
- 210000002798 bone marrow cell Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 238000005341 cation exchange Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 238000001516 cell proliferation assay Methods 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000004700 cellular uptake Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000004940 costimulation Effects 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 238000002784 cytotoxicity assay Methods 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 101150052825 dnaK gene Proteins 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 238000012137 double-staining Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 229940007078 entamoeba histolytica Drugs 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- AEOCXXJPGCBFJA-UHFFFAOYSA-N ethionamide Chemical compound CCC1=CC(C(N)=S)=CC=N1 AEOCXXJPGCBFJA-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 229940126864 fibroblast growth factor Drugs 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000007850 fluorescent dye Substances 0.000 description 1
- 230000005714 functional activity Effects 0.000 description 1
- 230000000799 fusogenic effect Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 108010008714 glucose-regulated protein 170 Proteins 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 210000004394 hip joint Anatomy 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 230000005917 in vivo anti-tumor Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940117681 interleukin-12 Drugs 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 229960000310 isoleucine Drugs 0.000 description 1
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 230000002934 lysing effect Effects 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 208000021039 metastatic melanoma Diseases 0.000 description 1
- 238000012737 microarray-based gene expression Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 108700043516 mouse H-2Kb Proteins 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 238000012243 multiplex automated genomic engineering Methods 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 235000019834 papain Nutrition 0.000 description 1
- 229940055729 papain Drugs 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 229940056360 penicillin g Drugs 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 108010011110 polyarginine Proteins 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 108091033319 polynucleotide Proteins 0.000 description 1
- 102000040430 polynucleotide Human genes 0.000 description 1
- 239000002157 polynucleotide Substances 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 235000019419 proteases Nutrition 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 238000004007 reversed phase HPLC Methods 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 239000012128 staining reagent Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 229960002385 streptomycin sulfate Drugs 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007970 thio esters Chemical class 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 230000003614 tolerogenic effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 108010062760 transportan Proteins 0.000 description 1
- PBKWZFANFUTEPS-CWUSWOHSSA-N transportan Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(N)=O)[C@@H](C)CC)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)CN)[C@@H](C)O)C1=CC=C(O)C=C1 PBKWZFANFUTEPS-CWUSWOHSSA-N 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229940030325 tumor cell vaccine Drugs 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000012762 unpaired Student’s t-test Methods 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 208000020416 vascular bone neoplasm Diseases 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940098232 yersinia enterocolitica Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4615—Dendritic cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/462—Cellular immunotherapy characterized by the effect or the function of the cells
- A61K39/4622—Antigen presenting cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464499—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5152—Tumor cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Definitions
- This invention relates to immunoregulation, and more particularly to T cell response regulation.
- Mammalian T lymphocytes recognize antigenic peptides bound to major histocompatibility complex (MHC) molecules on the surface of antigen presenting cells (APC).
- MHC major histocompatibility complex
- APC antigen presenting cells
- the antigenic peptides are generated by proteolytic degradation of protein antigens within the APC.
- the interaction of the T cells with the APC and the subsequent response of the T cells are qualitatively and quantitatively regulated by interactions between cell surface receptors on the T cells with both soluble mediators and ligands on the surface of APC.
- TAKAHASHI C. et al., Journal of Immunology, 1999, Vol. 162, No. 9, pages 5037-5040 disclose the use of an agonist 4-1BB antibody in combination with staphylococcal enterotoxin A (SEA).
- SEA staphylococcal enterotoxin A
- peripheral T cells will clonally expand. After expansion, there is a dramatic decrease in the frequency and absolute number of SEA-specific T cells.
- SEA is injected with an agonist mAb specific for 4-1BB in mice, clonal expansion of the CD4 V ⁇ 3 T cells is significantly increased. Furthermore, the deletion of expanded CD8 T cells was inhibited.
- mice bearing a weakly immunogenic tumor with an agonistic antibody specific for murine 4-1BB (also known as CD137) and a peptide fragment of a polypeptide expressed by the tumor resulted in regression of the tumor.
- an agonistic antibody specific for murine 4-1BB also known as CD137
- treatment of mice bearing a second weakly immunogenic tumor with the same 4-1BB antibody and autologous dendritic cells "primed” in vitro with cells of the tumor resulted in regression of the tumor.
- signaling via cell-surface 4-1BB molecules and providing an immunogenic stimulus (a) prevents induction of anergy in CD8+ T cells and (b) reverses already established anergy in the CD8+ T cells.
- the invention features (a) an antigen for which a T cell receptor is specific such as a tumor associated pcptide-epitope and (b) an agonistic 4-1BB-binding antibody) for use as a medicament or a combination of medicaments for generating an enhanced immune response in a subject.
- the invention also features an in vitro method of enhancing the response of a T cell in which a population of cells containing a T cell is incubated with (a) an antigen for which a T cell receptor is specific such as a peptide-epitope from an infectious microoganism and (b) an agonistic 4-1BB-binding antibody.
- the invention also embraces an in vitro method of activating a T cell, e.g., a CD8+ T cell or a CD4+ T cell.
- This method involves: (a) providing a cell sample comprising a T cell; and (b) culturing the cell sample with an antigen for which a T cell receptor is specific and an agonistic 4-1BB-binding antibody.
- Another aspect of the invention is a method of preventing induction of anergy or of reversing anergy in a T cell; the method includes contacting the T cell with: (a) an antigen for which a T cell receptor is specific; and (b) an agonistic 4.1BB-binding antibody.
- the contacting can be in vitro .
- the invention also features (a) an antigen for which a T cell receptor is specific and an agonistic 4-1BB-binding antibody; (b) a nucleic acid encoding the antigen and the agonistic 4-1BB-binding antibody ; (c) the antigen and a nucleic acid encoding the agonistic 4-1BB binding antibody; or (d) a nucleic acid encoding the antigen and a nucleic acid encoding the agonistic 4-1BB binding antibody for use as a medicament or a combination of medicaments for preventing induction of angergy or reversing anergy in a T cell in a subject.
- nucleic acid encoding the antigen - and a nucleic acid encoding the 4-1BB binding antibody the nucleic acid encoding the antigen and the nucleic acid encoding the 4-1BB binding antibody being in the same nucleic acid molecule.
- nucleic acid encoding the a ntigen or the 4-1BB-binding agent may be transfected or transduced into a cell, the cell being a cell, or a progeny of a cell, that prior to the transfection or the transduction, was obtained from a mammal.
- the agonistic 4-1BB binding antibody can be a functional fragment thereof.
- the antigen can be a (a) a tumor-associated antigen (TAA) or (b) a functional fragment of a TAA and it can be a polypeptide.
- TAA can be a molecule produced by a leukemia, a lymphoma, a neurological cancer, a melanoma, a breast cancer, a lung cancer, a head and neck cancer, a gastrointestinal cancer, a liver cancer, a pancreatic cancer, a genitourinary cancer, a prostate cancer, a renal cell cancer, a bone cancer, or a vascular cancer cell.
- the antigen -can be a dendritic cell that has a major histocompatibility complex (MHC) molecule with peptide-epitope bound thereto, the peptide-epitope being a fragment of a TAA or a fragment of a polypeptide produced by an infectious microorganism.
- MHC major histocompatibility complex
- the MHC molecule can be a MHC class I molecule or a MHC class II molecule.
- the antigen -can be also be a hybrid cell, e.g., a fusion product of a tumor cell and a dendritic cell.
- the antigen can be a tumor cell, a tumor cell lysate, a TAA, a peptide-epitope of a TAA, or a heat shock protein bound to peptide-epitope of protein expressed by a tumor cell.
- the antigen can also be a dendritic cell that has been incubated with tumor cells, a tumor cell lysate, a TAA, a peptide-epitope of a TAA, or a heat shock protein bound to peptide-epitope of protein expressed by a tumor cell.
- the cell can be transfected with or transformed with a nucleic acid encoding a cytokine or a growth factor, e.g., granulocyte macrophage-colony stimulating factor (GM-CSF).
- a cytokine or a growth factor, e.g., granulocyte macrophage-colony stimulating factor (GM-CSF).
- GM-CSF granulocyte macrophage-colony stimulating factor
- the antigen can be a molecule produced by an infectious microorganism, e.g., a virus such as a retrovirus, a bacterium, a fungus, or a protozoan parasite.
- an infectious microorganism e.g., a virus such as a retrovirus, a bacterium, a fungus, or a protozoan parasite.
- an "enhanced immune response” is obtained by administering to a subject antigen for which a T cell receptor is specitic and an agonistic 4-1BB-binding antibody.
- an appropriate antigen either stimulates no immune response in the subject or it stimulates an immune response in the subject that is detectably lower than a response stimulated by administration of the antigen and an agonistic 4-1BB-binding agent.
- an "anergic T cell” or an “anergized T cell” is a T cell whose ability to respond to an immunogenic stimulus, with respect to at least one activity of the T cell, has been partially or completely inhibited.
- an anergic or anergized T cell may lack or have a decreased ability to proliferate and produce interleukin-2 in response to an immunogenic stimulus but its ability to produce interferon- ⁇ in response to the immunogenic stimulus may be substantially intact.
- an anergic or anergized T cell may display a lack or a decrease in all the functional activities elicited by an immunogenic stimulus in such a T cell.
- reversing anergy in a T cell means fully or partially restoring the ability of the T cell to perform one or more functions in response to an immunogenic stimulus.
- preventing the induction of" anergy in a T cell means fully or partially inhibiting the induction of anergy in the T cell.
- an "agonistic 4-1BB-binding agent” is a substance that upon binding to a 4-1BB molecule on a target cell (e.g., a T cell) enhances the response of the target cell to an immunogenic stimulus.
- a "functional fragment of a tumor-associated antigen (TAA)” is a fragment of a TAA shorter than the full-length TAA but with greater than 10% (e.g., greater than 10%, greater than 20%, greater than 30%, greater than 40%, greater than 50%, greater than 60%, greater than 70%, greater than 80%, greater than 90%, greater than 95%, greater than 98%, greater than 99%, greater than 99.5%, or 100% or more) of the ability of the full-length TAA to activate an immune response in the presence or absence of an agonistic 4-1BB-binding agent.
- TAA that are polypeptides a "full-length" TAA is the mature TAA, i.e.. the polypeptide lacking its native signal sequence.
- a "peptide-epitope" of a polypeptide is a fragment of a polypeptide that binds to a major histocompatibility complex (MHC) molecule and is recognized in the form of a complex with the MHC molecule by an antigen specific receptor on a T cell (TCR).
- MHC molecules can be class I or class II MHC molecules.
- Polypeptide and “protein” are used interchangeably and mean any peptide-linked chain of amino acids, regardless of length or post-translational modification.
- the invention is based on the finding that treatment of mice bearing a weakly immunogenic tumor with an agonistic antibody specific for murine 4-1BB and a peptide fragment of a polypeptide expressed by the tumor resulted in regression of the tumor.
- treatment of mice bearing a second weakly immunogenic tumo r with the same 4-1BB antibody and autologous dendritic cells "primed" in vitro with cells of the tumor resulted in regression of the tumor.
- the inventors have also discovered that providing an immunogenic stimulus and a 4-1BB-mediated signal to a CD8+ T cell not only prevents induction of anergy in a CD8+ T cell, but can also reverse, partially or completely, already established anergy in a CD8+ T cell.
- the invention features methods of activating mammalian immune responses in which cells of the immune system are exposed to (a) an antigen for which a T cell receptor is specific and (b) an agonistic 4-1BB-binding antibody. Exposure of the cells to the antigen can occur before, during, or after exposure to the 4-1BB binding antibody. The two exposures will preferably be substantially simultaneous.
- Responses that are enhanced by the methods of the invention can be any immune response.
- the responses enhanced are preferably T cell responses.
- enhancement of a CD4+ T cell helper cell response can indirectly result in enhancement of a B cell antibody response.
- the activities of other cells of the immune system e.g., monocytes/macrophages, granulocytes (e.g., neutrophils), and natural killer cells
- monocytes/macrophages, granulocytes (e.g., neutrophils) are regulated by T cells.
- the methods of the invention can be used to enhance responses of any or all of these cell types.
- the invention also provides methods for preventing induction of anergy in r cells or reversing anergy in T cells already rendered anergic.
- the relevant T cells are contacted with an antigen for which a T cell receptor is specific and a 4-1BB-binding antibody. Contacting of the T cells with the antigen can occur before, during, or after contacting the T cells with the 4-1BB binding agent.
- an "immunogenic stimulus” is a stimulus delivered to a T cell via the antigen-specific T cell receptor (TCR) expressed on the surface of the T cell More commonly, but not necessarily, such a stimulus is provided in the form of an antigen for which the TCR is specific. While such antigens will generally be protein, they can also be carbohydrates, lipids, nucleic acids or hybrid molecules having components of two or more of these molecule types, e.g., glycoproteins or lipoproteins. However, the immunogenic stimulus can also be provided by other agonistic TCR ligands such as antibodies specific for TCR components (e.g., TCR ⁇ -chain or ⁇ -chain variable regions) or antibodies specific for the TCR-associated CD3 complex.
- TCR antigen-specific T cell receptor
- Immunogenic stimuli do not include antigen-non-specific stimuli provided by, for example, cytokines (e.g., interleukin-12), growth factors, co-stimulatory molecules, or adhesion molecules. While such stimuli can be exploited in the methods of the invention, they do not constitute the required immunogenic stimulus.
- Antigens useful as immunogenic stimuli include alloantigens (e.g., a MHC alloantigen) on, for example, an antigen presenting cell (APC) (e.g., a dendritic cell (DC), a macrophage, a monocyte, or a B cell).
- APC antigen presenting cell
- DC dendritic cell
- macrophage a monocyte, or a B cell
- DC of interest are interdigitating DC and not follicular DC; follicular DC present antigen to B cells.
- interdigitating DC are referred to herein as DC.
- Methods of isolating DC from tissues such as blood, bone marrow, spleen, or lymph node are known in the art, as are methods of generating them in vitro from precursor cells in such tissues.
- Also useful as immunogenic stimuli are polypeptide antigens and peptide-epitopes derived from them. Unprocessed polypeptides are processed by APC into peptide-epitopes that are presented to responsive T cells in the form of molecular completes with MHC molecules on the surface of the APC.
- Useful immunogenic stimuli also include a source of antigen such as a lysate of either tumor cells or cells infected with an infectious microorganism of interest.
- APC e.g., DC
- pre-exposcd e.g., by coculturing
- antigenic polypeptides, peptidc-epitopes of such polypeptides or lysates of tumor (or infected cells) can also be used as immunogenic stimuli.
- Such APC can also be "primed” with antigen by culture with a cancer cell or infected cell of interest; the cancer or infected cells can optionally be irradiated or heated (e.g., boiled) prior to the priming culture.
- APC especially DC
- antigen as an immunogenic stimulus can be provided in the form of cells (e.g., tumor cells or infected cells producing the antigen of interest).
- immunogenic stimuli can be provided in the form of cell hybrids formed by fusing APC (e.g., DC) with tumor cells [ Gong et al. (2000) Proc. Natl. Acad. Sci. USA 97(6):2716-2718 ; Gong et al. (1997) Nature Medicine 3(5):558-561 ; Gong et al. (2000) J. Immunol. 165(3):1705-1711 ] or infected cells of interest.
- APC e.g., DC
- IC immunogenic cells
- Cells or cell hybrids can be used (as immunogenic stimuli) untreated or they can be metabolically inhibited (e.g., by irradiation or exposure to a drug such as mitomycin-C) so as to substantially ablate their ability to divide.
- Tumor or infected cells used per se as an immunogenic stimulus or as IC for the production of cell hybrids will preferably, but not necessarily, be derived from the same donor as that of the T cell.
- the cell s are from a different donor, they will preferably share one MHC haplotype with the T cell.
- APC used to form cell hybrids will also preferably, but not necessarily, be derived from the same donor as the T cell. In the production of cell hybrids, either the APC or the IC will be preferably be from, or MHC-compatible with, the donor of the T cell. Alternatively, the APC and/or the IC can share one MHC haplotype (i.e., be semi-allogeneic) with the donor of the T cell.
- the cells or hybrids used as immunogenic stimuli will frequently be used in the presence of APC of the T cell donor (e.g., in in vivo applications), they can be fully MHC incompatible with the T cell.
- heat shock proteins bound to antigenic peptide-epitopes derived from antigens e.g., tumor-associated antigens or antigens produced by infectious microorganisms
- antigens e.g., tumor-associated antigens or antigens produced by infectious microorganisms
- Heat shock proteins of interest include, without limitation, glycoprotein 96 (gp96), heat shock protein (hsp) 90, hsp70, hsp110, glucose-regulated protein 170 (grp 170) and calreticulin.
- Immunogenic stimuli can include one or more (e.g., one, two, three, four, five, six, seven, eight, nine, ten, more) heat shock proteins isolated from tumor cells or infected cells.
- tumor or infected cells are preferably, but not necessarily, from the same subject (i) whose immune response is to be enhanced by a method of the invention or (ii) from whom T cells (whose response is to be enhanced by a method of the invention) were obtained.
- the tumor or infected cells can also be obtained, for example, from another individual having the same or a related tumor-type or infection as the subject.
- the heat shock protein can be isolated from mammalian cells expressing a transcriptosome prepared from tumor cells or inflected cells of interest.
- Immunogenic stimuli can be derived from a wide range of infectious microorganisms (e.g., bacteria, fungi including yeasts, viruses, and parasites such as protozoan parasites).
- infectious microorganisms e.g., bacteria, fungi including yeasts, viruses, and parasites such as protozoan parasites.
- relevant microorganisms include, without limitation, Mycobacteria tuberculosis, Salmonella enteriditis, Listeria monocytogenes, M.
- microbial proteins include, without limitation, the B subunit of heat labile enterotoxin of E. coli [ Konieczny et al. (2000) FEMS Immunol. Med. Microbiol. 27(4):321-332 ], heat-shock proteins, e.g., the Y. enterocolitica heat shock protein 60 [Konieczny et al. (2000) supra ; Mertz et al. (2000) J. Immunol. 164(3):1529-1537 ] and M. tuberculosis heat-shock proteins hsp60 and hsp 70, the Chlamydia trachomatis outer membrane protein [ Ortiz et al. (2000) Infect. Immun.
- E. coli outer membrane protein F [ Williams et al. (2000) Infect. Immun. 68(5):2535-2545 ], influenza virus hemagglutinins and neuramindases, retroviral (e.g., HIV) surface glycoproteins (e.g., HIV gp160/120), or retroviral tat or gag proteins.
- CTL are by virtue of their ability to kill target cells infected with any of a wide variety of intracellular pathogens (e.g., viruses, or intracellular bacteria and protozoans) potent mediators of immunity to such pathogens.
- intracellular pathogens e.g., viruses, or intracellular bacteria and protozoans
- helper T cells release a wide variety of cytokines that mediate pathogen-destructive inflammatory reponses.
- immunogenic stimuli useful in the invention can be any of a wide variety of tumor cells, APC “primed” with tumor cells, hybrid cells (see above), tumor-associated antigens (TAA), peptide-epitopes of such TAA, and APC “primed” with TAA or peptide-epitopes of them.
- TAA tumor-associated antigens
- a "TAA” is a molecule (e.g., a protein molecule) that is expressed by a tumor cell and either (a) differs qualitatively from its counterpart expressed in normal cells, or (b) is expressed at a higher level in tumor cells than in normal cells.
- a TAA can differ (e.g., by one or more amino acid residues where the molecule is a protein) from, or it can be identical to, its counterpart expressed in normal cells. It is preferably not expressed by normal cells. Alternatively, it is expressed at a level at least two-fold higher (e.g., a two-fold, three-fold, five-fold, ten-fold, 20-fold, 40-fold, 100-fold, 500-fold, 1,000-fold, 5,000-fold, or 15,000-fold higher) in a tumor cell than in the tumor cell's normal counterpart.
- two-fold higher e.g., a two-fold, three-fold, five-fold, ten-fold, 20-fold, 40-fold, 100-fold, 500-fold, 1,000-fold, 5,000-fold, or 15,000-fold higher
- tumors examples include, without limitation, hematological cancers such as leukemias and lymphomas, neurological tumors such as astrocytomas or glioblastomas, melanoma, breast cancer, lung cancer, head and neck cancer, gastrointestinal tumors such as gastric or colon cancer, liver cancer, renal cell cancer, pancreatic cancer, genitourinary tumors such ovarian cancer, vaginal cancer, bladder cancer, testicular cancer, prostate cancer or penile cancer, bone tumors, and vascular tumors.
- hematological cancers such as leukemias and lymphomas
- neurological tumors such as astrocytomas or glioblastomas, melanoma
- breast cancer such as astrocytomas or glioblastomas, melanoma
- lung cancer head and neck cancer
- gastrointestinal tumors such as gastric or colon cancer
- liver cancer liver cancer
- renal cell cancer pancreatic cancer
- genitourinary tumors such as ovarian cancer, vaginal cancer, bladder
- TAA include, without limitation, carcinoembryonic antigen (CEA), prostate specific antigen (PSA), MAGE (melanoma antigen) 1-4, 6 and 12, MUC (mucin) (e.g., MUC-1, MUC-2, etc.), tyrosinase, MART (melanoma antigen), Pmel 17(gp100), GnT-V intron V sequence (N-acetylglucoaminyltransferase V intron V sequence), Prostate Ca psm, PRAME (melanoma antigen), ⁇ -catenin, MUM-1-B (melanoma ubiquitous mutated gene product), GAGE (melanoma antigen) 1, BAGE (melanoma antigen) 2-10, c-ERB2 (Her2/neu), EBNA (Epstein-Barr Virus nuclear antigen) 1-6, gp75, human papilloma virus (HPV) E6 and E7, p53, lung resistance protein
- pathogenic agents e.g., tumor cells, infectious microorganisms, or cells infected with infectious agents
- pathogenic agents e.g., tumor cells, infectious microorganisms, or cells infected with infectious agents
- an agonistic 4-1BB-binding agent optionally given with one or more non-specific agents such as cytokines (see above)
- the pathogenic agents do not per se constitute an immunogenic stimulus for the purposes of the invention.
- an agonistic 4-1BB-binding agent and optionally one or more non-specific agents such as cytokines (see above)
- pathogenic agents e.g., tumor cells, infectious microorganisms, or cells infected with infectious agents
- the harbored pathogenic agents do not per se constitute an immunogenic stimulus for the purposes of the invention.
- the agonistic 4-1BB-binding agent can be an antibody specific for 4-1BB.
- antibody refers not only to whole antibody molecules, but also to antigen-binding fragments, e.g., Fab, F(ab') 2 , Fv, and single chain Fv fragments. Also included are chimeric antibodies.
- the antibody can be a polyclonal antibody or a monoclonal antibody (mAb)., e.g., the 2A mAb or the 5.9 and 5.10 mAbs described below.
- the agonistic 4-1BB-binding agent can be the natural 4-1BB ligand (4-1BBL) or a functional fragment of 4-1BB.
- a functional fragment of 4-1BB means a fragment of 4-1BB that is shorter than full-length, mature 4-1BBL and has at least 10 % (e.g., at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 98%, at least 99%, or 100% or more) of the ability of full-length mature 4-1 BBL to enhance the response of a T cell to antigen of interest.
- Methods of testing and comparing the ability of molecules to enhance the response of T cells are known to investigators in the field, e.g., methods (or simple modifications of those) described in the Examples.
- 4-1BB-binding agents e.g., antibodies
- bind to a domain of 4-1BB that is identical or overlapping with a domain to which 4-1BBL binds are not agonistic
- the invention is not limited by any particular mechanism of action. Methods to test for agonistic activity in a candidate 4-1BB-binding agent would be essentially the same as those referred to above for testing the ability of a fragment of 4-1BBL for its ability to enhance the response of T cell to an immunogenic stimulus and thus well-known to those in the art.
- the agonistic 4-1BB-binding agents can be added to the solution (e.g., blood or culture medium) containing the T cell. Alternatively, it can be secreted by or expressed on the surface of a cell in the vicinity of the T cell, e.g., an APC presenting an alloantigen or a peptide-epitope bound to an MHC molecule on the surface of the APC.
- a cell in the vicinity of the T cell, e.g., an APC presenting an alloantigen or a peptide-epitope bound to an MHC molecule on the surface of the APC.
- Such cells can also be tumor cells, infected cells, or the cell hybrids described above.
- the cell can be, but is not necessarily, the same cell presenting an alloantigen or a peptide-epitope bound to an MHC molecule to the T cell.
- the methods of the invention require the provision of an exogenous source of the 4-1BB-binding agent. It is understood that where the agonistic 4-1BB-binding agent used in the methods of the invention is one secreted by or expressed on the surface of a cell such as an APC, tumor cell, infected cell, or hybrid cell, it will not be an agonistic 4-1BB-binding agent (e.g., 4-1BBL) naturally expressed by such cells.
- an agonistic 4-1BB-binding agent e.g., 4-1BBL
- an agonistic 4-1BB-binding agent where the only source of an agonistic 4-1BB-binding agent is that on the surface of or secreted by an APC, the agonistic 4-1BB-binding agent will be encoded by a recombinant 4-1BB encoding nucleic acid molecule in the APC.
- fortuitous administration to a subject of an agonistic 4-1BB-binding agent present in, for example, blood, plasma, or serum administered to the subject for, e.g., therapeutic purposes does not per se constitute administration of an agonistic 4-1BB-binding agent for the purposes of the invention.
- the fortuitous presence of an agonistic 4-1BB-binding agent in culture medium used for immune cell (e.g., T cell) activating cultures does not per se constitute the agonistic 4-1BB-binding agent required to be present in the in vitro methods of activating T cells of the invention.
- the 4-1BB binding agent can be bound to the floor of a relevant culture vessel, e.g. a well of a plastic microtiter plate.
- the agonistic 4-1BB-binding agent will preferably, but not necessarily, bind to 4-1BB on the surface of a T cell whose response is enhanced by the methods of the invention.
- 4-1BB is expressed on cells other than T cells, e.g., natural killer (NK) cells and monocytes [ Melero et al. (1998) Cell. Immunol. 190:167-172 ; Kienzle et al. (2000) Int. Immunol. 12:73-82 ].
- NK natural killer
- binding of the T cell or the response of a bystander cell e.g., a B cell cell antibody response
- binding of a 4-1BB-binding agent to a CD4+ T cell can overcome anergy in a bystander CD4+ T cell or CD8+ T cell that is also exposed to an immunogenic stimulus by, for example, the action of cytokines produced by the CD4+ T cell to which the 4-1BB binding agent binds.
- binding of a 4-1BB-binding agent to a CD8+ T cell could overcome anergy in a bystander CD8+ T cell or CD4+ T cell exposed to an immunogenic stimulus.
- Short amino acid sequences can act as signals to direct proteins (e.g., immunogenic stimuli or agonistic 4-1BB-binding agents) to specific intracellular compartments.
- proteins e.g., immunogenic stimuli or agonistic 4-1BB-binding agents
- hydrophobic signal peptides e.g., MAISGVPVLGFFIIAVLMSAQESWA (SEQ ID NO:1)
- KFERQ SEQ ID NO:2
- other sequences e.g., MDDQRDLISNNEQLP (SEQ ID NO:3) direct polypeptides to endosomes.
- the peptide sequence KDEL (SEQ ID NO:4) has been shown to act as a retention signal for the ER.
- Each of these signal peptides, or a combination thereof, can be used to traffic, for example the immunogenic stimuli or agonistic 4-1BB-binding agents to appropriate cellular compartments.
- Other signal sequences of interest include the HIV tat transduction domain (RKKRRQRR; SEQ ID NO:5), the Antennapedia homeodomain (RQIKIWFPNRRMKWKK; SEQ ID NO:6) and signal sequences derived from fibroblast growth factor [ Lin et al. (1995) J. Biol. Chem. 220:14255-14258 ], transportan [ Pooga et al. (1998) FASEB J.
- DNAs encoding the polypeptides containing targeting signals can be generated by PCR or other standard genetic engineering or synthetic techniques.
- the immunogenic T cell stimuli and agonistic 4-1BB-binding agents can have the amino acid sequences of naturally occurring molecules or they can have substitutions. Such substitutions will preferably be conservative substitutions. Conservative substitutions typically include substitutions within the following groups: glycine and alanine; valine, isoleucine, and leucine; aspartic acid and glutamic acid; asparagine, glutamine, serine, and threonine; lysine, histidine, and arginine; and phenylalanine and tyrosine.
- Polypeptides useful for the invention also include those described above, but modified for in vivo use by the addition, at the amino- and/or carboxyl-terminal ends, of a blocking agent to facilitate survival of the relevant polypeptide in vivo. This can be useful in those situations in which the peptide termini tend to be degraded by proteases prior to cellular uptake.
- blocking agents can include, without limitation, additional related or unrelated peptide sequences that can be attached to the amino and/or carboxyl terminal residues of the peptide to be administered. This can be done either chemically during the synthesis of the peptide or by recombinant DNA technology by methods familiar to artisans of average skill.
- blocking agents such as pyroglutamic acid or other molecules known in the art can be attached to the amino and/or carboxyl terminal residues, or the amino group at the amino terminus or carboxyl group at the carboxyl terminus can be replaced with a different moiety.
- the peptide compounds can be covalently or noncovalently coupled to pharmaceutically acceptable "carrier" proteins prior to administration.
- Peptidomimetic compounds that are designed based upon the amino acid sequences of polypeptides of interest.
- Peptidomimetic compounds are synthetic compounds having a three-dimensional conformation (i.e., a "peptide motif") that is substantially the same as the three-dimensional conformation of a selected peptide.
- the peptide motif provides the peptidomimetic compound with the ability to activate an immune response (in the case of immunogenic stimuli) and enhance an immune response (in the case of the agonistic 4-1BB-binding agents).
- Peptidomimetic compounds can have additional characteristics that enhance their in vivo utility, such as increased cell permeability and prolonged biological half-life.
- the peptidomimetics typically have a backbone that is partially or completely non-peptide, but with side groups that are identical to the side groups of the amino acid residues that occur in the peptide on which the peptidomimetic is based.
- Several types of chemical bonds e.g., ester, thioester, thioamide, retroamide, reduced carbonyl, dimethylene and ketomethylene bonds, are known in the art to be generally useful substitutes for peptide bonds in the construction of protease-resistant peptidomimetics.
- Molecules useful as immunogenic stimuli and agonistic 4-1BB-binding agents can be produced by any of a wide range of methods known in the art. They can be purified from natural sources (e.g., from any of the pathogenic agents listed herein). Smaller peptides (fewer than 100 amino acids long) and other non-protein molecules can be conveniently synthesized by standard chemical means known to those in the art. In addition, both polypeptides and peptides can be manufactured by standard in vitro recombinant DNA techniques and in vivo transgenesis using nucleotide sequences encoding the appropriate polypeptides or peptides (see Nucleic Acids section below).
- the transcriptional/translational regulatory elements referred to above include but are not limited to inducible and non-inducible promoters, enhancers, operators and other elements that are known to those skilled in the art and that drive or otherwise regulate gene expression.
- Such regulatory elements include but are not limited to the cytomegalovirus hCMV immediate early gene, the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage A, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase, the promoters of acid phosphatase, and the promoters of the yeast ⁇ -mating factors.
- the expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (for example, E. coli and B. subtilis ) transformed with recombinant bacteriophage DNA, plasmid DNA, or cosmid DNA expression vectors containing a nucleic acid molecules encoding immunogenic stimuli or agonistic 4-1BB-binding agents; yeast (for example, Saccharomyces and Pichia ) transformed with recombinant yeast expression vectors containing a nucleic acid encoding immunogenic stimuli or agonistic 4-1BB-binding agents; insect cell systems infected with recombinant virus expression vectors (for example, baculovinis) containing a nucleic acid encoding immunogenic stimuli or agonistic 4-1BB-binding agents; plant cell systems infected with recombinant virus expression vectors (for example, cauliflower mosaic virus (CaMV) or tobacco mosaic virus (TMV)) or transformed with recombinant plasmid
- Cells transfected or transduced with the expression vectors of the invention can then be used, for example, for large or small scale in vitro manufacture of an immunogenic stimulus or agonistic 4-1BB-binding agent by methods known in the art.
- methods known in the art In essence, such.methods involve culturing the cells under conditions that maximize production of the polypeptide and isolating the polypeptide from the cells or from the culture medium.
- the immunogenic stimuli and/or agonistic 4-1BB-binding agents be purified.
- Methods for purifying biological macromolecules e.g., proteins
- the degree of purity of the macromolecules can be measured by any appropriate method, e.g., column chromatography, polyacrylamide gel electrophoresis, or HPLC analysis.
- a T cell whose response is enhanced, whose anergy is reversed, or in which induction of anergy is prevented by the methods of the invention can be a CD4+ T cell or a CD8+ T cell.
- the invention is not limited by: (a) the T cell having any particular phenotype (e.g., CD4+ or CD8+) or function (e.g., cytotoxicity, helper activity, immune deviating activity, or suppressive activity); or (b) the MHC molecules by which the T cell is restricted being of any particular class.
- CD4+ CTL that recognize antigenic peptides bound to MHC class II molecules are known in the art.
- CD4+ CTL that recognize peptides bound to MHC class I molecules and CD8+ CTL that recognize antigenic peptides bound to MHC class II molecules have also been described.
- T cells with helper and/or immune deviating activity are CD4+ T cells and recognize antigenic peptides bound to MHC class II molecules, these activities have also been subserved in MHC class I restricted CD8+ T cells.
- immunosuppressive T cells are CD8+ T cells
- CD4+ T cells with immunosuppressive activity have also been demonstrated.
- the methods of the invention are applicable to all these T cells.
- Preferred responses will be those of MHC class I restricted CTL and MHC class II restricted CD4+ helper/immune deviating T cells. Responses of MHC class I restricted CTL are particularly preferred.
- the methods of the invention can be performed in vitro .
- a 4-1BB-binding agent can be added to in vitro assays (e.g., in T cell proliferation assays) designed to test for immunity to an antigen of interest in a subject from which the T cells were obtained. Addition of a 4-1BB-binding agent to such assays would be expected to result in a more potent, and therefore more readily detectable, in vitro response.
- the methods of the invention will preferably be ex vivo (see below).
- lymphoid cells consisting of or including T cells obtained from a mammalian subject are cultured with any of the above described immunogenic stimuli and agonistic 4-1BB-binding agents.
- the lymphoid cells can be from a subject pre-exposed to a relevant antigen (in any of the forms described above); alternatively, the donor of the lymphoid cells need not have been exposed to the antigen.
- the cultures can also be supplemented with one or move cytokines or growth factors such as, without limitation, interleukin-(IL-)1, IL-2, IL-3, IL-4, IL-6, IL-7, IL-12, IL-13, I-15, interferon- ⁇ (IFN- ⁇ ), tumor necrosis factor- ⁇ (TNF- ⁇ ), granulocyte macrophage colony-stimulating factor (GM-CSF), or granulocyte-colony stimulating factor (G-CSF).
- the cultures can be "restimulated” as often as necessary.
- the cultures can also be monitored at various times to ascertain whether the desired level of immune reactivity (e.g., CTL or helper T cell activity) has been attained.
- lymphoid cells including T cells (CD4+ and/or CD8+ T cells), are isolated from a subject and exposed to one or more immunogenic stimuli and one or more agonistic 4-1BB-binding antibodies in vitro (see above).
- T cells can be, for example, anergic T cells in which it is desired to reverse anergy.
- the lymphoid cells can be exposed once or multiply (e.g., 2, 3, 4, 6, 8, or 10 times).
- the level of immune activity (e.g., CTL activity) in the lymphoid cells can be tested after one or more exposures. Once the desired activity and level of that activity is attained, the cells are reintroduced into the subject (or another subject) via any of the routes listed herein.
- the therapeutic or prophylactic efficacy of this ex vivo approach is dependent on the ability of the ex vivo activated lymphocytes to exert, directly or indirectly, a neutralizing or cytotoxic effect on, for example, infectious microorganisms, host cells infected with microorganisms, or tumor cells.
- An alternative ex vivo strategy can involve transfecting or transducing cells obtained from a subject with one or more polynucleotides encoding one or more T cell specific immunogenic stimuli and one or more agonistic 4-1BB-binding antibodies. The transfected or transduced cells are then returned to the subject or another subject.
- hemopoietic cells e.g., bone marrow cells, macrophages, monocytes, dendritic cells, or B cells
- they could also be any of a wide range of types including, without limitation, fibroblasts, epithelial cells, endothelial cells, keratinocytes, or muscle cells in which they act as a source of the said one or more immunogenic stimuli and one or more agonistic 4-1BB-binding agents for as long as they survive in the subject.
- hemopoietic cells that include the above APC, would be particularly advantageous in that such cells would be expected to home to, among others, lymphoid tissue (e.g., lymph nodes or spleen) and thus the immunogenic stimuli and agonistic 4-1BB-binding agents would be produced in high concentration at the site where they exert their effect, i.e., enhancement of an immune response.
- lymphoid tissue e.g., lymph nodes or spleen
- the APC expressing the exogenous can be, but are not necessarily, the same APC that presents an alloantigen or antigenic peptide to the relevant T cell.
- the agonistic 4-1BB-binding agents can be secreted by the APC or expressed on its surface. Prior to administering recombinant APC to a subject, they can optionally be exposed to the above-listed sources of antigens or antigenic peptides of interest, e.g., those of tumors or infectious microorganisms. The same genetic constructs and trafficking sequences described for the in vivo approach can be used for this ex vivo strategy. Furthermore, tumor cells or hybrid cells produced by fusion of APC (e.g., dendritic cells) and tumor cells can be transfected or transformed by one or more vectors encoding said one or more agonistic 4-1BB-binding agents.
- APC e.g., dendritic cells
- Such cells are then administered to a subject with the relevant cancer where, due to their expression of the exogenous agonistic 4-1BB-binding agents (on their cell surface or by secretion), they can stimulate enhanced tumoricida T cell immune responses.
- an agent e.g., ionizing irradiation or mitomycin C
- tumor cells which, after transfection or transformation with said agonistic 4-1BB-binding agent encoding nucleic acids, are administered to a subject with cancer can have been obtained from an individual other than the subject.
- tumor cells used for the production of hybrid cells that express said recombinant agonistic 4-1BB-binding agents and are administered to a subject with cancer can have been obtained from an individual other than the subject.
- the ex vivo methods can include the steps of harvesting cells (e.g., tumor cells or APC) from a subject, culturing the cells, transducing them with one or more expression vectors, and maintaining the cells under conditions suitable for express ion of the said immunogenic stimuli and/or said agonistic 4-1BB-binding agents. These methods are known in the art of molecular biology.
- the transduction step is accomplished by any standard means used for ex vivo gene therapy, including calcium phosphate, lipofection, electroporation, viral infection, and biolistic gene transfer. Alternatively, liposomes or polymeric microparticles can be used.
- Cells that have been successfully transduced are then selected, for example, for expression of the coding sequence or of a drug resistance gene.
- the cells may then be lethally irradiated (if desired) and injected or implanted into the patient.
- the methods can include the additional step of making the above-described cells hybrids that are injected or implanted into the patient
- An immunogenic stimulus can be provided in the form of a peptide-epitope and agonistic 4-1BB-binding antibody in the form of either a nucleic acid encoding it or cells transformed with a nucleic acid encoding it.
- the invention features antibodies that bind specifically to human and mouse 4-1BB.
- Such antibodies can be polyclonal antibodies present in the serum or plasma of animals (e.g., mice, rabbits, rats, guinea pigs, sheep, horses, goats, cows, or pigs that have been immunized with the relevant 4-1BB polypeptide (or a peptide fragment thereof) using methods, and optionally adjuvants, known in the art.
- Such polyclonal antibodies can be isolated from, for example, serum, plasma, or ascites by methods known in the art.
- Monoclonal antibodies (mAb) that bind to 4-1BB polypeptides or fragments are also encompassed by the invention. These mAbs include those produced by the 2A, 5.9, and 5.10 hybridomas (see Examples).
- the resulting antibody can be produced by a number of in vivo and in vitro methods known in the art.
- the hybridoma can be cultured in vitro in a suitable medium for a suitable length of time, followed by the recovery of the desired antibody from the supernatant.
- the length of time and medium are known or can be readily determined.
- recombinant antibodies specific for 4-1BB such as chimeric and humanized monoclonal antibodies comprising both human and non-human portions
- chimeric and humanized monoclonal antibodies can be produced by recombinant DNA techniques known in the art, for example, using methods described in Robinson et al., International Patent Publication PCT/US86/02269 ; Akira et al., European Patent Application 184, 187 ; Taniguchi, European Patent Application 171,496 ; Morrison et al., European Patent Application 173,494 ; Neuberger et al., PCT Application WO 86/01533 ; Cabilly et al., U.S. Patent No.
- antibody fragments and derivatives which contain at least the functional portion of the antigen binding domain of an antibody that binds specifically to 4-1BB.
- Antibody fragments that contain the binding domain of the molecule can be generated by known techniques.
- fragments include, but are not limited to: F(ab') 2 fragments that can be produced by pepsin digestion of antibody molecules; Fab fragments that can be generated by reducing the disulfide bridges of F(ab') 2 fragments; and Fab fragments that can be generated by treating antibody molecules with papain and a reducing agent. See, e.g., National Institutes of Health, 1 Current Protocols In Immunology, Coligan et al., ed.
- Antibody fragments also include Fv (e.g., single chain Fv (scFv)) fragments, i . e ., antibody products in which there are few or no constant region amino acid residues.
- Fv e.g., single chain Fv (scFv)
- An scFv fragment is a single polypeptide chain that includes both the heavy and light chain variable regions of the antibody from which the ScFv is derived. Such fragments can be produced, for example, as described in U.S. Patent No. 4,642,334 .
- Tumor models and peptides C3 cells generated from HPV-16-/EJras-transformed C57BL/6 (B6) mouse embryo cells [ Feltkamp et al. (1993) Eur. J. Immunol. 23:2242-2249 ], were a gift from Dr. W. Martin Kast (Loyola University, Chicago, IL).
- a line of EL4 cells (EL4E7) transfected with cDNA encoding the human papilloma virus-16 (HPV-16) E7 polypeptide [ Tindle et al. (1995) Clin. Exp. Immunol. 101:265-271 ] was a gift from Dr. Germain J.P. Fernando (University of Queensland, Brisbane, Australia).
- the TC-1 cell line [ Liu et al. (1996) Cancer Res. 56:21-6 ] was a gift from Dr. T.C. Wu (Johns Hopkins University, Baltimore, MD) and the B16-F10 melanoma line [ Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90:3539-3543 ] was a gift from Dr. Glenn Dranoff (Dana-Farber Cancer Institute, Boston, MA).
- the EL4, RMA-S and S49.1 murine T cell lymphoma lives were of B6 origin and were purchased from the American Type Culture Collection (Manassas, VA).
- P815R The regressor P815 mastocytoma (P815R), which has been previously described [ Nieland et al. (1999) J. Cell Biochem 73:145-152 ], was obtained from Dr. W. Martin Kast, Loyola University, Chicago, IL. All cell lines were maintained in a complete tissue culture medium of RPMI 1640 (Life Technologies, Carlsbad, CA) supplemented with 10% fetal bovine serum (FBS) (HyClone, Logan, UT), 25 mM HEPES, 2mM glutamine, 100 U/ml penicillin G and 100 ⁇ g/ml streptomycin sulfate.
- FBS fetal bovine serum
- the E7 peptide (RAHYNIVTF) (SEQ ID NO:7) contained the minimal H-2D b -restricted CTL epitope [ Feltkamp et al. (1993) Eur. J. Immunol. 23:2242-2249 ] of HPV-16 E7 protein.
- the trp-2 peptide (SVYDFFVWL) (SEQ ID NO:8) is a H-2K b -restricted epitope first identified in the B16 melanoma [ Bloom et al. (1997) J. Exp. Med.185:453-459 ; Schreurs et al. (2000) Cancer Res. 60:6995-7001 ].
- the Vp2 control peptide (FHAGSLLVFM) (SEQ ID NO:9) contains an H-2D b -restricted CTL epitope derived from the Theiler's Murine Encephalomyelitis Virus [ Johnson et al. (1999).J. Virol. 73:3702-3708 ].
- the OVA (257-264) peptide (SIINFEKL) (SEQ ID NO:10) (referred to in the OT-1 T cell anergy experiments described in Examples 10-13 as the "OVA peptide") is a H-2K b -restricted CTL epitope derived from chicken ovalbumin [ Curtsinger et al. (1998) J. Immunol.
- the OVA (55-62) peptide (KVVRFDKL) (SEQ ID NO: 11) used as a "control peptide" in the OT-1 T cell anergy experiments described in Examples 10-13 is a H-2K b -restricted CTL epitope from chicken ovalbumin [E1- Shami et al. (1999) Eur. J. Immunol. 29:3295-3301 ]
- the P1A (35-43) peptide (LPYLGWLVF) (SEQ ID NO:12) is an H-2L d restricted CTL epitope.
- peptides were synthesized by the Mayo Molecular Biology Core Facility and the purity of the peptides was >90% by reverse-phase HPLC purification.
- the peptides were dissolved in dimethyl sulfoxide (DMSO) and reconstituted in phosphate buffered saline (PBS) to a final concentration of 1 mg/ml (5% DMSO) for administration to mice.
- DMSO dimethyl sulfoxide
- PBS phosphate buffered saline
- mice Female B6 mice were purchased from the National Cancer Institute (Frederick, MD). Age-matched mice, 6-10 weeks old, were used for all experiments. Tumor cells in 0.1 ml of PBS were injected subcutaneously (s.c.) into the right shaved flanks. Mice were given 1 x 10 6 C3 cells or 4 x 10 6 EL4E7 cells. Tumor size (the average of two perpendicular diameters in mm) was measured weekly as previously described [ Tamada et al. (2000) Nature Med. 6:283-289 ].
- mice For lung metastases models, 1 x 10 4 TC-1 or 1 x 10 5 B16-F10 cells were injected in 0.5 ml of Hank's Buffered Salt Solution into the tail vein of mice. Mice bearing subcutaneous tumors were immunized intradermally (i.d.) at a site contralateral to the tumor with 50 ⁇ g of peptide emulsified in incomplete Freund's adjuvant (IFA) (Sigma Chemicals, St. Louis, MO). Mice bearing lung metastases were immunized bilaterally i.d. with a total of 100 ⁇ g of peptide emulsified in IFA. Antibodies administered to mice were injected intraperitoneally (i.p.) in 0.5 ml of PBS.
- IFA incomplete Freund's adjuvant
- OT-1 transgenic mice which have been previously described [ Strome et al. (2002) Cancer Research 62:1884-1889 ], were obtained from Dr. Larry Pease, Mayo Clinic, Rochester, MN. All the CD8+ T cells of the OT-1 mice express an antigen specific T cell receptor (TCR) specific for the OVA (257-264) peptide bound to the murine H-2K b MHC class I molecule.
- TCR antigen specific T cell receptor
- cDNA encoding the extracellular domain of mouse 4-1BB was amplified from cDNA produced from RNA isolated from concanavilin A-activated spleen cells using sequence specific primers and was fused to the CH 2 -CH 3 domain of mouse IgG2a in the expression plasmid pmIgV [ Chapoval et al. (2000) Nature Med. 6:283-289 ].
- the resulting expression vector was transfected into CHO cells.
- the protein in the culture supernatants of a transfected clone was purified using a HiTrap Protein G-Sepharose column (Amersham Pharmacia Biotech, Piscataway, NJ) and dialyzed into lipopolysaccharide-free PBS.
- a rat monoclonal antibody (mAb) against 4-1 BB was generated by immunizing a Lewis rat (Harlan Sprague Dawley, Indianapolis, IN) with mouse 4-1BBIg.
- Hybridomas were produced by fusing rat spleen cells with mouse Sp2/0 myeloma cells and the culture supernatants were screened by ELISA.
- the hybridoma secreting the mAb 2A was selected for further experiments.
- Hybridoma 2A was grown in RPMI 1640 supplemented with 10% low IgG FBS (Life Technologies) and 25 mM HEPES and supernatant was harvested and concentrated using a tangential flow miniplate concentrator (Millipore, Bedford, MA).
- the 2A mAb was purified from the concentrated supernatant using a 5 ml HiTrap Protein G-Sepharose column (Amersham Pharmacia Biotech, Piscataway, NJ). The purified mAb was dialyzed against PBS and concentrated using a Centriprep concentrator (Millipore, Bedford. MA). The isotype of the 2A mAb was determined using biotinylated, isotype-specific antibodies (Caltag Laboratories, Burlingame, CA). It was found to be an IgG2a antibody with kappa light chains.
- mAb specific for mouse CD3, CD28, 4-1BB, fluorescein isothiocyanate-(FITC-) conjugated CD8, CD69, CD25, CD49A, and isotype control mAb, and Cy-Chrome-conjugated CD8 mAb were purchased from PharMingen (San Diego, CA).
- the FITC-conjugated goat anti-rat IgG antibody was purchased from Biosource International (Camarillo, CA).
- Rat IgG antibodies (Sigma Chemical, Gilbertsville, PA) were used as controls.
- H-2D b major histocompatibility complex (MHC) class I molecule bound to either the E7 peptide (H-2D b -E7) or the control Vp2 peptide (H-2D b -Vp2) were prepared as previously described [ Johnson et al. (1999) J. Virol. 73:3702-3708 ]. Briefly, H-2D b ⁇ -chain and human ⁇ 2 -microglobulin were isolated from a bacterial expression system and subsequently folded in the presence of excess peptide. The folded monomeric complexes were desalted and biotinylated.
- the monomeric complexes were conjugated to strepavidin labeled with the fluorescent dye, phycoerythin (PE), thereby forming fluorescent tetrameric complexes.
- PE phycoerythin
- the PE-labeled tetramers generated were then purified by size exclusion gel filtration.
- a tetramer composed of four mouse H-2K b molecules bound to the OVA (257-264) peptide and labeled with PE (sometimes referred to below as the "OVA tetramer") was obtained from the NIH tetramer core facility (Atlanta. GA).
- T cell costimulation assay The method used to assay costimulatory activity of mAb was described previously [ Tamada et al. (2000) Nature Med. 6:283-289 ].
- nylon wool (NW)-purified mouse splenic T cells (2.5 x 10 6 /ml) were added to 96-well plates which had been coated with a mAb against CD3 (0.1 ⁇ g/ml) and the indicated concentrations of rat IgG or mAb 2A.
- the proliferation of T cells was assessed by the addition of 1 ⁇ Ci/well of [ 3 H]-thymidine ( 3 H-TdR) to the 3-day cultures 15 hours before harvesting of the cultures onto fiber glasstilters.
- 3 H-TdR incorporated into the T cells was measured in a MicroBeta TriLux liquid scintillation counter (Wallac, Turku, Finland).
- T cells were positively selected using FITC conjugated mAbs against CD4 and CD8, metal microbeads coated with antibody specific for FITC, and a magnet as instructed by the manufacturer (Miltenyi Biotec, Auburn, CA). The purity of the isolated T cells was routinely greater than 95%, as assessed by flow cytometry using a mAb against CD3. Purified T cells (2.5 x 10 6 cells/ml) from mouse spleens were stimulated in the wells of 24-well tissue culture plates coated with mAbs against CD3 (5 ⁇ g/ml) and CD28 (1 ⁇ g/ml).
- T cells were collected and stained for 30 min at 4°C with 1 ⁇ g mAb 2A, either alone or in the presence of 4-1BBIg (2 ⁇ g/ml), in 50 ⁇ l PBS supplemented with 3% FBS and 0.02% azide. The cells were washed and incubated an additional 30 min at 4°C with FITC-conjugated goat antibody specific for rat IgG. After washing the cells were fixed in 1% paraformaldehyde and fluorescence was analyzed with a FACS (Becton Dickinson, Mountain View, CA). S49.1 cells were stained in a similar fashion.
- FACS Becton Dickinson, Mountain View, CA
- Tumor-draining lymph nodes from immunized mice were harvested on day 7 and stained with PE-labeled H-2D b- E7 or H-2D b -Vp2 tetrameric complexes and FITC-conjugated CD8 as previously described [ Johnson et al. (1999) J. Virol. 73:3702-3708 ].
- Five x 10 6 TDLN cells were incubated with 2.5 x 10 -5 UV-irradiated C3 cells for 4 days. Cells were subsequently stained with the PE-labeled tetramers and FITC-conjugated CD8. After extensive washing, cells were re-suspended in PBS with 750 ng/ml propidium iodide. Gates were drawn to include viable CD8 + cells only.
- T cells were purified from spleens and lymph nodes of mice using microbead coated with antibody specific for Thy1.2 according to the manufacturers instructions (Miltenyi Biotec, San Diego, CA). Purified Thy1.2+ cells were subsequently stained with the OVA tetramer described above. Positively stained cells were sorted using a FACSVantage Flow Cytometry System (B D Immunocytometry Systems, San Jose, CA). At least 90% of the sorted cells were both OVA tetramer positive and CD8+.
- effector cells were obtained by co-culturing draining LN cells with irradiated C3 cells for 4 days. Effector cells were harvested from the cultures and tested for CTL activity using a standard 4-hr 51 Cr release assay with tumor cell targets at the indicated effector to target cell (E:T) ratios. Peptide-pulsed target cells were generated by culturing the target cells with 10 ⁇ g/ml of the peptide at 28°C for 18 hours prior to use. The CTL assay used for the OT-1 T cell anergy experiments was performed similarly using the target cells indicated below.
- Murine DC were prepared from bone marrow. Mice were sacrificed and dipped in 70% ethanol (EtOH). After removing excess EtOH, the hind limbs were exposed and the hip joint dislocated. Muscle parenchyma was removed and the bones placed briefly in 70% EtOH and then in complete medium (CM; RPMI 1640, 10% heat inactivated FBS (Hyclone Laboratories, Inc., Logan, UT), Fungizone (0.5 ⁇ g/ml), ⁇ -ME (2 x 10 -5 M), sodium pyruvate (1 mM), non-essential amino acids (0.1 mM), penicillin and streptomycin (100 ⁇ g/ml), glutamine (2 mM) and Gentamycin (50 ⁇ g/ml)).
- CM complete medium
- Both ends of the bones were cut to expose the marrow and a 3cc syringe (filled with CM) with a 25 gauge needle was used to eject the marrow into a 10mm cell culture dish, containing CM.
- the cells were separated from stromal components by straining through a steel sieve and, after pelleting by centrifugation, were resuspended in 1.0 ml medium of containing 10 ⁇ g/ml of anti-class II (I-A b ) mAb, anti-Mac 3 mAb, anti-CD8a mAb (HO2.2), anti-CD45R (B220) mAb, anti-CD3e mAb, and anti-GR-1 mAb (all from PharMingen, Inc.
- mice Induction of T cell anergy 3-7 x 10 6 lymph node and spleen cells from OT-1 mice were injected intravenously (i.v.; tail vein) into wild type B6 mice in 0.5 ml Hanks balanced salt solution (HBSS) (Cellgro, Herndon, Virginia). 12-24 hours later, experimental mice were given 0.5 mg of OVA (257-264) peptide i.v. in 0.5 ml total volume, while control mice were given OVA (55-62) peptide (or PBS alone in some experiments) in a similar fashion. On the day of peptide administration, and again 3 days later, mice were given 100 ⁇ g of either rat IgG or anti-CD 137 mAb intraperitoneally (i.p.).
- HBSS Hanks balanced salt solution
- mice were sacrificed at various time points following peptide administration and the total number of OT-1 cells present in the spleen and lymph nodes of each mouse was determined by OVA tetramer staining.
- spleens were harvested from the mice. After lysing red blood cells in Ack lysis buffer, the spleen cells were resuspended in RPMI tissue culture medium supplemented as described above for the medium used to culture tumo cell lines and plated in triplicate into the wells of a 96-well plate at a density of 5.5x10 5 cells per well in final volume of 200 ⁇ l per well.
- One group of cells was unstimulated while a second group was restimulated with 1 ng/ml of OVA peptide.
- the frequency of OVA-specific T cells was determined using the H-2K b -OVA (257-264) tetramer.
- the absolute number of OT-1 cells added to each well could be calculated prior to restimulation in vitro .
- Supernatants were collected from the wells in each group 48 and 72 hours after restimulation and IL-2 (48 hr) and IFN- ⁇ (72 hr) production was measured by sandwich ELISA following the manufacturer's instructions (PharMingen, San Diego, California).
- T cells The proliferation of T cells was assessed by the addition of 1 ⁇ Ci/well [ 3 H]-thymidine during the last 15 hours of the 3-day culture. [ 3 H]-thymidine incorporation was measured in a MicroBeta TriLux liquid scintillation counter (Wallac, Turku, Finland). Antigen specific proliferation or cytokine production per OT-1 cell was calculated by subtracting any nonspecific proliferation (or cytokine production) observed in the unstimulated groups from the proliferation (or cytokine production) observed in the peptide stimulated groups. This was then divided by the number of OT-1 cells (10 3 ) initially present in the well prior to restimulation to derive the net change in cpm ( ⁇ cpm) per 10 3 OT-1 cells.
- OT-1 cells were adoptively transferred into wild type recipients. Anergy was induced by the intravenous administration of 0.5 mg OVA peptide as described above. Alternatively, mice received only control peptide or PBS and were considered "na ⁇ ve" at the time of rechallenge with the antigen. Ten days later mice were given 0.5 mg OVA peptide or control peptide intravenously. Mice received 100 ⁇ g of either rat IgG or anti-CD137. Mice were sacrificed at various time points following rechallenge with the OVA peptide and the number of OT-1 cells present in the spleen and lymph nodes of each mouse was determined by tetramer analysis, as before.
- mAb 2A binds specifically to the mouse T cell lymphoma S49.1 that constitutively expresses 4-1BB (as demonstrated by staining with 1AH2, a commercially available anti-4-1BB mAb ( Fig. 1B )).
- Immobilized mAb 2A also enhanced T cell proliferation in a dose-dependent fashion in the presence of a suboptimal dose of anti-CD3 mAb ( Fig. 1C ). Therefore, 2A is a costimulatory mAb similar to others previously described [ Melero et al. (1997) Nature Med. 3:682-685 ; Shuford et al. (1997) 186:47-55].
- EL4E7 is a thymoma transfected to express the HPV-16 E7 gene and C3 is an embryonic epithelial cell line transformed with HPV-16 and the ras oncogene. Since both tumor lines express the E7 gene of HPV-16, CTL responses to the E7 gene product can be monitored.
- groups of mice bearing established EL4E7 or C3 tumors were injected i.p. with 2A (100 ⁇ g) at days 7 and 10. As shown in Fig.
- mice bearing C3 tumors were first inoculated subcutaneously (s.c.) with C3 cells and subsequently (3-7 days later) treated with mAb 2A or control rat IgG. Seven days later, TDLN were harvested, re-stimulated in vitro with irradiated C3 cells, and the CTL activity of cells harvested from cultures was tested in a standard 51 Cr release assay. As shown in Fig.
- the frequency of E7 (49-57) specific T cells in C3 TDLN was determined by double staining with FITC conjugated anti-CD8 mAb and PE-labeled E7 tetramer. Consistent with the findings on CTL activity, less than 0.1 % of CD8 + T cells in TDLN from C3-bearing mice were E7-specific, even after in vitro re-stimulation with irradiated C3 cells. This value represents a threshold of "undetected CTL" in the assay since similar results were also obtained using cells from na ⁇ ve mice. Furthermore, treatment with the 2A mAb failed to expand E7-specific CTL in C3 TDLN ( Fig. 4A, B ).
- E7-specific CTL activity was examined in the mice after immunization with the E7 (49-57) peptide that contains a H-2D b restricted CTL epitope. Seven days after peptide immunization, draining LN were harvested, restimulated with irradiated C3 cells and the frequency of E7 specific CD8 + T cells was determined using the fluorescent E7 tetramer. Immunization with the E7 peptide caused a significant increase of cells that bound the E7 tetramer. Such cells were not detectable after immunization with a control Vp2 peptide.
- E7-specific CTL Treatment with mAb 2A resulted in a further increase in the frequency of E7-specific CTL ( Fig. 5A ). Similar results were obtained by immunization of naive mice ( Fig. 5B ). Therefore, E7-specific CTL are present in C3-bearing mice, but are neither activated nor deleted by the C3 cells. Thus E7-specific CTL ignore antigens presented by the C3 tumor. In addition, anti-4-1BB mAb alone is unable to break this unaware state.
- mice On the day of immunization and 3 days later, mice were given 100 ⁇ g of mAb 2A or a control rat IgG i.p. Tumor size was assessed weekly. Data shown was pooled from several experiments. b 21 days following treatment, the mean tumor diameter was calculated for those tumors which had failed to completely regress. c The Unpaired Student's T-test was used to calculate p-values comparing the mean tumor diameter of the treatment group which received both the E7 peptide and mAb 2A with those of the control groups.
- the TC-1 tumor line is derived from primary lung epithelial cells co-transformed with both the HPV-16 E6, HPV-16 E7 and ras oncogenes [ Liu et al. (1996) Cancer Res. 56:21-6 ]. Therefore, the E7 peptide could be used as an immunogen.
- B16-F10 is a highly metastatic melanoma line, which presents the H-2K b -restricted trp-2 peptide [ Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90:3539-3543 ; Bloom et al. (1997) J. Exp.
- mice were injected intravenously (i.v.) with 10 4 TC-1 cells to establish lung metastases.
- the mice were injected s.c. with the E7 peptide and i.p. with the 2A mAb (COPP).
- COPP 2A mAb
- the administration of mAb 2A alone was insufficient to prolong survival in the tumor-bearing mice, as all of the mice died within 20 days.
- E7 peptide immunization alone did prolong survival, although all of the mice were dead by day 35.
- COPP treatment trp-2 peptide and mAb 2A led to a significant survival advantage for all the mice and long-term survival (>90 days) in 20% of treated mice. Therefore, combined treatment with an antigenic, MHC class I restricted peptide and anti-4-1BB mAb (COPP) may be therapeutic for established, poorly immunogenic tumors.
- the 2A mAb (or control rat IgG) was administered three days after each test vaccination. Tumor growth was measured in a blinded fashion to determine therapeutic efficacy.
- Fig. 8 80% of animals treated with rat IgG alone developed tumors (group 3; Fig. 8 top right panel).
- animals treated with tumor "primed" C and rat IgG (group 1; Fig. 8 , bottom right panel) or mAb 2A alone (group 4; Fig 8 , top left panel) there was therapeutic efficacy in 3 out of 5 mice.
- a strategy similar to that described above for generation of mAbs specific for murine 4-1BB was used.
- a soluble 4-1BB fusion protein composed of an extracellular fragment of human 4-1BB and the CH3-CH3 domain of human IgG1 was engineered. Mice immunized with this fusion protein produced polyclonal antibodies to 4-1BB. Spleens from these animals were fused with SP2/0 mouse myelomas to produce hybridomas that were screened by fluorescence flow cytometry with 293 cells transfected with cDNA encoding human 4-1BB. Two hybridomas (5.9 and 5.10) producing TgG1 mAbs showed human 4-1BB-specific staining.
- Example 7 In order to determine whether the two anti-human 4-1BB mAbs described in Example 7 have the ability costimulate a T cell response, a standard in vitro costimulation assay was performed. Briefly, purified human T-cells were cultured with (a) antibody specific for human CD3 coated onto the well-bottoms of 96-well tissue culture plates at various concentrations and (b) varying concentrations of the 5.9 mAb, the 5.10 mAb, or normal mouse IgG, all also coated (at a concentration of 10 ⁇ g/ml) onto the well-bottoms of the 96-well tissue culture plates. 3 H-TdR incorporation measured after a 48-hour culture period was used to determine T cell proliferation. ( Fig. 9 ). Both anti-human 4-1BB stimulated significant T cell proliferation, thereby demonstrating the T cell costimulatory potential of these antibodies.
- mice were injected i.v. with 5 x 10 5 B16-F10 melanoma cells in order to generate disseminated metastases. On days 3, 7, and 11 the mice were immunized s.c.
- B16-GM-CSF murine GM-CSF
- mice injected i.p. with 100 ⁇ g of either rat IgG or mAb 2A as indicated below.
- the B16-GM-CSF cells were generated essentially as described in Dranoff et al. (1993) Proc. Natl. Acad. Sci. USA 90:3539-3543 .
- mice were monitored for survival ( Fig. 10 ). Mice immunized with B-16-GM-CSF and mAb 2A showed enhanced survival over mice immunized with B 16-GM-CSF and rat IgG.
- Intravenous (i.v.) delivery of antigen is an established approach to induce anergy in CD4 + T cells [ Vaiserskikh et al. (2001) Transplantation 72:685-693 ; Thorstenson et al. (2001) J. Immunol. 167:188-195 ; and Bercovici et al. (1999) Eur. J. Immunol. 29:345-354 ].
- antigen-specific T cells exposed to a high dose of soluble antigen become unresponsive to the antigen; this is demonstrated by the inability of the T cells to proliferate and secrete IL-2 upon exposure to the antigen in vitro in the presence of APC [ Jacobs et. al. (1994) Immunology 82:294-300 ].
- This approach was adapted by the inventors to examine the induction of anergy in CD8 + T cells.
- CD8 + T cells were OVA tetramer-positive (i.e., were OT-1 T cells) in the mice treated with control peptide
- the proportion of CD8 + T cells that were OT-1 T cells in the OVA-treated mice was 6.8% ( Fig. 11 ).
- OT-1 cell blastogenesis was also observed in the OVA-treated mice, as demonstrated by the increase in forward scatter of the cells from these mice by FACS analysis.
- more than 50% of the OT-1 cells in the OVA-treated mice expressed the T-cell activation markers, CD69 and CD25 ( Fig. 11 ).
- mice treated as described above were rechallenged i.v.10 days later with either a control peptide or the OVA peptide.
- naive mice i.e., mice that had not received the initial injection of OVA peptide
- spleens and lymph nodes were harvested from the mice and the total numbers of OT-1 cells in pooled spleen and lymph node samples were determined by OVA tetramer staining. A greater than 4-fold expansion was observed in the na ⁇ ve mice treated with OVA.
- OT-1 cells retained their effector function following the induction of anergy
- splenocytes from B6 mice injected with OT1 T cells and a single dose of OVA as described above were restimulated with OVA peptide in vitro.
- the OT-1 cells pre-exposed to OVA were incapable of proliferating in vivo , they secreted IFN- ⁇ upon restimulation with OVA in vitro at a level similar to naive OT-1 T cells ( Fig. 12C ).
- Example 11 CD137 signaling prevents the induction of OT-1 T cell anergy
- mice Following adoptive transfer of OT-1 cells into naive B6 mice and the administration of OVA peptide, mice were injected i.p. with either a CD137 mAb (clone 2A) or control rat IgG. Mice were sacrificed at various time points up to 21 days following injection of the OVA peptide and the total number of OT-1 cells present in the spleens and lymph nodes in each group of mice was determined by OVA tetramer staining. As shown in Fig. 13A , treatment with anti-CD137 mAb following OVA administration led to an approximately ten-fold increase in the number OT-1 cells compared to those mice that received the control rat IgG.
- mice to which OT-1 T cells had been adoptively transferred and that were injected with either PBS, OVA peptide and anti-CD137 mAb, or OVA peptide and control rat IgG were sacrificed ten days following peptide (or PBS) administration.
- the number of OT-1 cells present in the pooled splenocytes from each group of mice was determined by OVA tetramer staining.
- the splenocytes were subsequently restimulated in vitro with an optimal concentration of OVA peptide.
- OT-1 proliferation and IL-2 secretion were measured 72 and 48 hours later, respectively.
- OT-1 T cells The proliferation of OT-1 T cells, as measured by [ 3 H]-thymidine incorporation, was determined on a per cell basis. Unlike the naive OT1 T cells from mice that had received PBS, OT-1 cells from mice that were given the OVA peptide and control rat IgG failed to proliferate following in vitro restimulation ( Fig. 13B ). Furthermore, FACS analysis demonstrated that virtually 100% of the OT-1 T cells from the mice previously exposed to OVA peptide expressed the late activation marker VLA-4, in contrast to the OT-1 cells in the control peptide-treated mice ( Fig. 13C ). In sharp contrast, proliferation was observed in OT-1 T cells from those mice that received anti-CD137 mAb and OVA peptide.
- IL-2 production was not observed following restimulation of the anergic OT-1 cells from OVA peptide and anti-CD 137 mAb treated mice, a finding consistent with their lack of proliferation ( Fig. 13B ) whereas OT-1 cells from the anti-CD137 treated mice secreted IL-2 to an extent comparable with naive OT-1 ( Fig. 3B ); this finding provided further evidence that CD 137 signaling prevented the induction of T cell anergy.
- mice were injected i.v. with OVA peptide as described above in order to induce anergy in the OT-1 T cells, Ten days later, the mice were injected i.p. with anti-CD137 mAb together with OVA peptide. Mice were sacrificed 2, 5 and 10 days following treatment and the total number of OT-1 T cells was determined by OVA tetramer staining. As shown in Fig.
- OVA peptide OT-1 T cell anergic mice were prepared as described above. Ten days after the injection of OVA peptide, the mice were given various combinations of control peptide or OVA peptide and control rat IgG or anti-CD137 mAb. Three days later, the mice were sacrificed and the total number of OT-1 cells determined. OT-1 cell expansion was only observed in the group of mice that received both OVA peptide and anti-CD137 mAb ( Fig. 14B ).
- OT-1 T cells were sorted by FACS following staining with the OVA tetramer from the OVA-tolerized mice 5 days after challenge with OVA peptide and CD 137 mAb and were used as effector cells in a standard 4-hour 51 Cr-release assay for cytotoxicity against OVA-pulsed EL4 and control EL4 cells ( Fig. 14D ; "Anergic (OVA + 2A)").
- OT-1 cells were identically sorted from mice that, instead of initially being injected with the OVA peptide, were injected with the control peptide and then 10 days later were challenged with the OVA peptide and either rat IgG ("OVA + rat IgG") or anti-CD137 mAb ("OVA + 2A"); the cell sorting cytotoxicity testing, as for the experimental group, were performed 5 days after the peptide challenge and mAb/control IgG treatment. As shown in Fig. 14D , approximately 20% specific lysis was observed at an E:T ratio of 10 to 1 in those mice that had received the control IgG.
- P815R is a clonal variant of highly tumorigenic P815 mastocytoma, which unlike the parent P815 tumor, regresses spontaneously after inoculation into syngeneic DBA/2 mice [ Nieland et al. (1999) J. Cell Biochem. 73:145-152 ].
- Administration of a peptide epitope of P1A, a non-mutated self tumor antigen [ Van den Eynde et al. (1991) J. Exp. Med.
- mice were first tolerized with P1A peptide in IFA for 10 days and were subsequently challenged with P815R cells. Three days following tumor challenge, mice were given control rat IgG or anti-CD137 mAb. In mice treated with the control rat IgG, 90% of the mice developed progressively growing tumors ( Fig. 15B , left panel). In contrast, anti-CD137 mAb treatment led to tumor regression in 100% of mice ( Fig. 15B , right panel).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Claims (70)
- (a) Antigène pour lequel un récepteur de cellule T est spécifique, et(b) anticorps agoniste liant 4-1BB,
destinés à une utilisation sous la forme d'un médicament ou d'une combinaison de médicaments afin de générer une réponse immunitaire améliorée chez un sujet. - Antigène et anticorps selon la revendication 1, où l'antigène est (a) un antigène associé à une tumeur (TAA) ou (b) un fragment fonctionnel d'un TAA.
- Antigène et anticorps selon la revendication 1, où l'antigène est un polypeptide.
- Antigène et anticorps selon la revendication 2, où le TAA est une molécule produite par une cellule cancéreuse sélectionnée à partir du groupe constitué des cellules d'une leucémie, d'un lymphome, d'un cancer neurologique, d'un mélanome, d'un cancer du sein, d'un cancer des poumons, d'un cancer des voies aéro-digestives supérieures, d'un cancer des voies gastro-intestinales, d'un cancer du foie, d'un cancer du pancréas, d'un cancer des voies génito-urinaires, d'un cancer de la prostate, d'un cancer des cellules rénales, d'un cancer des os et d'un cancer des voies vasculaires.
- Antigène et anticorps selon la revendication 1, où l'antigène est une molécule produite par un micro-organisme infectieux.
- Antigène et anticorps selon la revendication 5, où le micro-organisme infectieux est un virus.
- Antigène et anticorps selon la revendication 6, où le virus est un rétrovirus.
- Antigène et anticorps selon la revendication 5, où le micro-organisme infectieux est sélectionné à partir du groupe constitué d'une bactérie, d'un champignon et d'un protozoaire parasite.
- Antigène et anticorps selon la revendication 1, où le sujet est un être humain.
- Antigène et anticorps selon la revendication 1, où l'antigène est une cellule dendritique comprenant une molécule de complexe majeur d'histocompatibilité (CMH) ayant un épitope à peptide lié à celle-ci, où l'épitope à peptide est un fragment d'un TAA ou un fragment d'un polypeptide produit par un micro-organisme infectieux.
- Antigène et anticorps selon la revendication 10, où la molécule de CMH est une molécule de CMH de classe I.
- Antigène et anticorps selon la revendication 10, où la molécule de CMH est une molécule de CMH de classe II.
- Antigène et anticorps selon la revendication 1, où la réponse immunitaire est une réponse d'une cellule T.
- Antigène et anticorps selon la revendication 13, où la cellule T est une cellule T CD8+.
- Antigène et anticorps selon la revendication 13, où la cellule T est une cellule T CD4+.
- Antigène et anticorps selon la revendication 1, où l'antigène est une cellule hybride.
- Antigène et anticorps selon la revendication 16, où la cellule hybride est un produit de fusion d'une cellule tumorale et d'une cellule dendritique.
- Antigène et anticorps selon la revendication 1, où l'antigène est une cellule tumorale, un lysat de cellule tumorale, un TAA, un épitope à peptide d'un TAA, ou une protéine de choc thermique liée à un épitope à peptide de protéine exprimé par une cellule tumorale.
- Antigène et anticorps selon la revendication 1, où l'antigène est une cellule dendritique qui a été incubée avec des cellules tumorales, un lysat de cellule tumorale, un TAA, un épitope à peptide d'un TAA, ou une protéine de choc thermique liée à un épitope à peptide exprimé par une cellule tumorale.
- Antigène et anticorps selon la revendication 18, où la cellule tumorale est transfectée ou transformée avec un acide nucléique codant une cytokine ou un facteur de croissance.
- Antigène et anticorps selon la revendication 20, où la cytokine est un facteur stimulant la formation et le développement de colonie de macrophages et de granulocytes (GM-CSF).
- (a) Antigène pour lequel un récepteur de cellule T est spécifique et anticorps agoniste liant 4-1BB,(b) acide nucléique codant l'antigène et l'anticorps agoniste liant 4-1BB,(c) antigène et acide nucléique codant l'anticorps agoniste liant 4-1BB,
ou(d) acide nucléique codant l'antigène et acide nucléique codant l'anticorps agoniste liant 4-1BB,
destinés à une utilisation sous la forme d'un médicament ou d'une combinaison de médicaments afin de prévenir l'induction d'anergie ou d'inverser une anergie dans une cellule T chez un sujet. - Acide nucléique codant l'antigène et acide nucléique codant l'anticorps agoniste liant 4-1BB selon la revendication 22, où l'acide nucléique codant l'antigène et l'acide nucléique codant l'anticorps liant 4-1BB sont la même molécule d'acide nucléique.
- Acide nucléique codant l'antigène et acide nucléique codant l'anticorps agoniste liant 4-1BB selon la revendication 22, où l'acide nucléique codant l'antigène ou l'anticorps liant 4-1BB est transfecté ou transduit dans une cellule, où la cellule est une cellule, ou une descendance d'une cellule qui, avant la transfection ou la transduction, a été obtenue à partir d'un mammifère.
- Antigène et anticorps selon l'une quelconque des revendications précédentes, où l'anticorps est un fragment de liaison d'antigène, en particulier Fab, F(ab')2, Fv ou un fragment de Fv à une seule chaîne.
- Utilisation(a) d'un antigène pour lequel un récepteur de cellule T est spécifique, et(b) d'un anticorps agoniste liant 4-1BB,
pour la fabrication d'un médicament ou d'une combinaison de médicaments afin de générer une réponse de cellule T améliorée chez un sujet. - Utilisation selon la revendication 26, dans laquelle l'antigène est (a) un antigène associé à une tumeur (TAA) ou (b) un fragment fonctionnel d'un TAA.
- Utilisation selon la revendication 26, dans laquelle l'antigène est un polypeptide.
- Utilisation selon la revendication 27, dans laquelle le TAA est une molécule produite par une cellule cancéreuse sélectionnée à partir du groupe constitué des cellules d'une leucémie, d'un lymphome, d'un cancer neurologique, d'un mélanome, d'un cancer du sein, d'un cancer des poumons, d'un cancer des voies aéro-digestives supérieures, d'un cancer des voies gastro-intestinales, d'un cancer du foie, d'un cancer du pancréas, d'un cancer des voies génito-urinaires, d'un cancer de la prostate, d'un cancer des cellules rénales, d'un cancer des os et d'un cancer des voies vasculaires.
- Utilisation selon la revendication 26, dans laquelle l'antigène est une molécule produite par un micro-organisme infectieux.
- Utilisation selon la revendication 30, dans laquelle le micro-organisme infectieux est un virus.
- Utilisation selon la revendication 31, dans laquelle le virus est un rétrovirus.
- Utilisation selon la revendication 30, dans laquelle le micro-organisme infectieux est sélectionné à partir du groupe constitué d'une bactérie, d'un champignon et d'un protozoaire parasite.
- Utilisation selon la revendication 26, dans laquelle le sujet est un être humain.
- Utilisation selon la revendication 26, dans laquelle l'antigène est une cellule dendritique comprenant une molécule de complexe majeur d'histocompatibilité (CMH) ayant un épitope à peptide lié à celle-ci, où l'épitope à peptide est un fragment d'un TAA ou un fragment d'un polypeptide produit par un micro-organisme infectieux.
- Utilisation selon la revendication 35, dans laquelle la molécule de CMH est une molécule de CMH de classe I.
- Utilisation selon la revendication 35, dans laquelle la molécule de CMH est une molécule de CMH de classe II.
- Utilisation selon la revendication 26, dans laquelle la cellule T est une cellule T CD8+.
- Utilisation selon la revendication 26, dans laquelle la cellule T est une cellule T CD4+.
- Utilisation selon la revendication 26, dans laquelle l'antigène est une cellule hybride.
- Utilisation selon la revendication 40, dans laquelle la cellule hybride est un produit de fusion d'une cellule tumorale et d'une cellule dendritique.
- Utilisation selon la revendication 26, dans laquelle l'antigène est une cellule tumorale, un lysat de cellule tumorale, un TAA, un épitope à peptide d'un TAA, ou une protéine de choc thermique liée à un épitope à peptide de protéine exprimé par une cellule tumorale.
- Utilisation selon la revendication 26, dans laquelle l'antigène est une cellule dendritique qui a été incubée avec des cellules tumorales, un lysat de cellule tumorale, un TAA, un épitope à peptide d'un TAA, ou une protéine de choc thermique liée à un épitope à peptide exprimé par une cellule tumorale.
- Utilisation selon la revendication 42, dans laquelle la cellule tumorale est transfectée ou transformée avec un acide nucléique codant une cytokine ou un facteur de croissance.
- Utilisation selon la revendication 44, dans laquelle la cytokine est un facteur stimulant la formation et le développement de colonie de macrophages et de granulocytes (GM-CSF).
- Utilisation(a) d'un antigène pour lequel un récepteur de cellule T est spécifique et d'un anticorps agoniste liant 4-1BB,(b) d'un acide nucléique codant l'antigène et l'anticorps agoniste liant 4-1BB,(c) de l'antigène et d'un acide nucléique codant l'anticorps agoniste liant 4-1BB,
ou(d) d'un acide nucléique codant l'antigène et d'un acide nucléique codant l'anticorps agoniste liant 4-1BB,
pour la fabrication d'un médicament ou d'une combinaison de médicaments afin de prévenir l'induction d'anergie ou d'inverser une anergie dans une cellule T chez un sujet. - Utilisation selon la revendication 46, dans laquelle l'acide nucléique codant l'antigène et l'acide nucléique codant l'anticorps liant 4-1BB sont la même molécule d'acide nucléique.
- Utilisation selon la revendication 46, dans laquelle l'acide nucléique codant l'antigène ou l'anticorps liant 4-1BB est transfecté ou transduit dans une cellule, où la cellule est une cellule, ou une descendance d'une cellule qui, avant la transfection ou la transduction, a été obtenue à partir d'un mammifère.
- Utilisation selon l'une quelconque des revendications 26 à 48, dans laquelle l'anticorps est un fragment de liaison d'antigène, en particulier Fab, F(ab')2, Fv ou un fragment de Fv à une seule chaîne.
- Procédé in vitro destiné à activer une cellule T, le procédé comprenant la mise en culture d'un échantillon de cellule comprenant une cellule T avec un antigène pour lequel un récepteur de cellule T est spécifique et un anticorps agoniste liant 4-1BB.
- Procédé in vitro destiné à prévenir l'induction d'anergie ou d'inverser une anergie dans une cellule, le procédé comprenant la mise en contact de la cellule T avec :(a) un antigène pour lequel un récepteur de cellule T est spécifique, et(b) un anticorps agoniste liant 4-1BB.
- Procédé selon la revendication 51, dans lequel l'antigène est (a) un antigène associé à une tumeur (TAA) ou (b) un fragment fonctionnel d'un TAA.
- Procédé selon la revendication 51, dans lequel l'antigène est un polypeptide.
- Procédé selon la revendication 52, dans lequel le TAA est une molécule produite par une cellule cancéreuse sélectionnée à partir du groupe constitué des cellules d'une leucémie, d'un lymphome, d'un cancer neurologique, d'un mélanome, d'un cancer du sein, d'un cancer des poumons, d'un cancer des voies aéro-digestives supérieures, d'un cancer des voies gastro-intestinales, d'un cancer du foie, d'un cancer du pancréas, d'un cancer des voies génito-urinaires, d'un cancer de la prostate, d'un cancer des cellules rénales, d'un cancer des os et d'un cancer des voies vasculaires.
- Procédé selon la revendication 51, dans lequel l'antigène est une molécule produite par un micro-organisme infectieux.
- Procédé selon la revendication 55, dans lequel le micro-organisme infectieux est un virus.
- Procédé selon la revendication 56, dans lequel le virus est un rétrovirus.
- Procédé selon la revendication 55, dans lequel le micro-organisme infectieux est sélectionné à partir du groupe constitué d'une bactérie, d'un champignon et d'un protozoaire parasite.
- Procédé selon la revendication 51, où le procédé comprend la mise en contact de la cellule T avec une cellule dendritique comprenant une molécule de complexe majeur d'histocompatibilité (CMH) ayant un épitope à peptide lié à celle-ci, où l'épitope à peptide est un fragment d'un TAA ou un fragment d'un polypeptide produit par un micro-organisme infectieux.
- Procédé selon la revendication 59, dans lequel la molécule de CMH est une molécule de CMH de classe I.
- Procédé selon la revendication 59, dans lequel la molécule de CMH est une molécule de CMH de classe II.
- Procédé selon la revendication 51, dans lequel la cellule T est une cellule T CD8+.
- Procédé selon la revendication 51, dans lequel la cellule T est une cellule T CD4+.
- Procédé selon la revendication 51, où le procédé comprend la mise en contact de la cellule T avec une cellule hybride.
- Procédé selon la revendication 64, dans lequel la cellule hybride est un produit de fusion d'une cellule tumorale et d'une cellule dendritique.
- Procédé selon la revendication 51, où le procédé comprend la mise en contact de la cellule T avec une cellule tumorale, un lysat de cellule tumorale, un TAA, un épitope à peptide d'un TAA, ou une protéine de choc thermique liée à un épitope à peptide de protéine exprimé par une cellule tumorale.
- Procédé selon la revendication 51, où le procédé comprend la mise en contact de la cellule T avec une cellule dendritique qui a été incubée avec des cellules tumorales, un lysat de cellule tumorale, un TAA, un épitope à peptide d'un TAA, ou une protéine de choc thermique liée à un épitope à peptide exprimé par une cellule tumorale.
- Procédé selon la revendication 66, dans lequel la cellule tumorale est transfectée ou transformée avec un acide nucléique codant une cytokine ou un facteur de croissance.
- Procédé selon la revendication 67, dans lequel la cytokine est un facteur stimulant la formation et le développement de colonie de macrophages et de granulocytes (GM-CSF).
- Procédé selon l'une quelconque des revendications 50 à 69, dans lequel l'anticorps est un fragment de liaison d'antigène, en particulier Fab, F(ab')2, Fv ou un fragment de Fv à une seule chaîne.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US32800401P | 2001-10-09 | 2001-10-09 | |
US328004P | 2001-10-09 | ||
PCT/US2002/032364 WO2003049755A1 (fr) | 2001-10-09 | 2002-10-09 | Amelioration des reponses immunitaires par des agents liant 4-1bb |
Publications (3)
Publication Number | Publication Date |
---|---|
EP1434596A1 EP1434596A1 (fr) | 2004-07-07 |
EP1434596A4 EP1434596A4 (fr) | 2004-12-15 |
EP1434596B1 true EP1434596B1 (fr) | 2009-07-08 |
Family
ID=23279079
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP02802551A Expired - Lifetime EP1434596B1 (fr) | 2001-10-09 | 2002-10-09 | Amelioration des reponses immunitaires par des anticorps agonistes liant 4-1bb |
Country Status (7)
Country | Link |
---|---|
US (3) | US7651686B2 (fr) |
EP (1) | EP1434596B1 (fr) |
AT (1) | ATE435655T1 (fr) |
AU (1) | AU2002364935A1 (fr) |
DE (1) | DE60232895D1 (fr) |
ES (1) | ES2328025T3 (fr) |
WO (1) | WO2003049755A1 (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA3016482A1 (fr) | 1999-11-30 | 2001-06-07 | Mayo Foundation For Medical Education And Research | Nouvelle molecule immunoregulatrice b7-h1, |
ES2328025T3 (es) | 2001-10-09 | 2009-11-06 | Mayo Foundation For Medical Education And Research | Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb. |
AU2003249247A1 (en) * | 2002-07-15 | 2004-02-02 | Mayo Foundation For Medical Education And Research | Treatment and prophylaxis with 4-1bb-binding agents |
US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
US20070253961A1 (en) * | 2004-06-09 | 2007-11-01 | Ulsan Industrial Education Foundation | Pharmaceutical Composition Comprising the Anti-4-1Bb Antibody for Treating or Preventing Rheumatoid Arthritis |
WO2006042237A2 (fr) | 2004-10-06 | 2006-04-20 | Mayo Foundation For Medical Education And Research | B7-h1 et procedes de diagnostic, de pronostic et de traitement du cancer |
EP1851244A4 (fr) * | 2005-02-15 | 2009-04-15 | Gtc Biotherapeutics Inc | Anticorps anti-cd137 en tant qu'agent dans le traitement de cancers et variante de glycosylation dudit anticorps |
US20060182744A1 (en) * | 2005-02-15 | 2006-08-17 | Strome Scott E | Anti-CD137 antibody as an agent in the treatment of cancer and glycosylation variants thereof |
WO2006088464A2 (fr) * | 2005-02-15 | 2006-08-24 | Gtc Biotherapeutics, Inc. | Procede d'utilisation d'un anticorps anti-cd137 en tant qu'agent de radio-immunotherapie ou radio-immunodetection |
US20080019905A9 (en) * | 2005-02-18 | 2008-01-24 | Strome Scott E | Method of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection |
CN101484470B (zh) * | 2005-10-21 | 2014-07-23 | 阿伊沃生物制剂有限公司 | 具有增强的抗体依赖性细胞毒性活性的抗体及其生产方法和用途 |
WO2007082154A2 (fr) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | Methode permettant de detecter un cancer a l'aide de b7-h1 et de b7-h4 |
WO2007082144A2 (fr) * | 2006-01-05 | 2007-07-19 | Mayo Foundation For Medical Education And Research | Methode permettant de detecter un cancer a l'aide de b7-h1 et de survivine |
MY160857A (en) * | 2006-02-03 | 2017-03-31 | Malaysian Palm Oil Board | A cancer vaccine |
WO2007124361A2 (fr) * | 2006-04-20 | 2007-11-01 | Mayo Foundation For Medical Education And Research | B7-h1 soluble |
WO2009042773A1 (fr) * | 2007-09-25 | 2009-04-02 | University Of Miami | Lymphocytes t spécifiques de tumeur transférés de manière adoptive, stimulés ex vivo à l'aide d'amplicons de virus de l'herpès |
WO2009111315A2 (fr) * | 2008-02-29 | 2009-09-11 | Mayo Foundation For Medical Education And Research | Méthodes de réduction de l’inflammation granulomateuse |
US20110229460A1 (en) * | 2008-05-01 | 2011-09-22 | Gtc Biotherapeutics, Inc. | anti-cd137 antibody as an agent in the treatment of inflammatory conditions |
ES2377785B2 (es) | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento del ojo seco. |
PL2614082T3 (pl) * | 2010-09-09 | 2019-02-28 | Pfizer Inc. | Cząsteczki wiążące 4-1BB |
EP3834851A1 (fr) | 2010-12-30 | 2021-06-16 | Laboratoire Français du Fractionnement et des Biotechnologies | Glycols en tant qu'agents pathogènes inactifs |
US9647989B2 (en) | 2011-04-27 | 2017-05-09 | Symantec Corporation | System and method of data interception and conversion in a proxy |
WO2012145825A1 (fr) * | 2011-04-27 | 2012-11-01 | Perspecsys Inc. | Système et procédé d'obscurcissement de données lors de l'interception d'une communication avec un nuage |
JP5643716B2 (ja) * | 2011-05-31 | 2014-12-17 | 楽天株式会社 | 情報処理システム、情報処理方法、情報処理装置、情報処理端末、プログラム及び記録媒体 |
EP3594231A1 (fr) | 2013-02-13 | 2020-01-15 | Laboratoire Français du Fractionnement et des Biotechnologies | Anticorps anti-tnf-alpha hautement galactosylatés et leurs utilisations |
CN105263319A (zh) | 2013-02-13 | 2016-01-20 | 法国化学与生物科技实验室 | 具有经修饰的糖基化的蛋白及其生产方法 |
US9302005B2 (en) | 2013-03-14 | 2016-04-05 | Mayo Foundation For Medical Education And Research | Methods and materials for treating cancer |
ES2935257T3 (es) * | 2013-03-15 | 2023-03-03 | Univ Chicago | Métodos y composiciones relacionadas con la actividad de las células T |
US10611826B2 (en) | 2013-07-05 | 2020-04-07 | Laboratoire Français Du Fractionnement Et Des Biotechnologies | Affinity chromatography matrix |
US10259875B2 (en) | 2013-10-01 | 2019-04-16 | Mayo Foundation For Medical Education And Research | Methods for treating cancer in patients with elevated levels of BIM |
KR101503341B1 (ko) | 2014-03-12 | 2015-03-18 | 국립암센터 | 자가암항원 특이적 cd8+ t 세포의 분리 및 증식방법 |
WO2015179654A1 (fr) | 2014-05-22 | 2015-11-26 | Mayo Foundation For Medical Education And Research | Distinction d'anticorps anti-b7-h1 agonistes et antagonistes |
WO2016014148A1 (fr) | 2014-07-23 | 2016-01-28 | Mayo Foundation For Medical Education And Research | Ciblage d'adn-pkcs et de b7-h1 pour traiter le cancer |
MX2017010159A (es) * | 2015-02-06 | 2017-12-18 | Heat Biologics Inc | Vector que expresa conjuntamente vacunas y moléculas coestimuladoras. |
EP3258959A4 (fr) | 2015-02-22 | 2018-10-17 | Sorrento Therapeutics, Inc. | Agents thérapeutiques de type anticorps se liant à cd137 |
EP3277313B1 (fr) * | 2015-04-02 | 2021-06-23 | Cancure Limited | Agents et compositions destinés à induire une réponse immunitaire |
WO2017075045A2 (fr) | 2015-10-30 | 2017-05-04 | Mayo Foundation For Medical Education And Research | Anticorps anti-b7-h1 |
WO2018085854A1 (fr) * | 2016-11-07 | 2018-05-11 | Advaxis, Inc. | Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 |
US11512134B2 (en) | 2017-08-01 | 2022-11-29 | Eli Lilly And Company | Anti-CD137 antibodies |
EP3523332B1 (fr) | 2017-01-06 | 2021-12-29 | Eutilex Co., Ltd. | Anticorps anti-4-1 bb humain et son utilisation |
US11459394B2 (en) | 2017-02-24 | 2022-10-04 | Macrogenics, Inc. | Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof |
MX2019012223A (es) | 2017-04-13 | 2019-12-09 | Agenus Inc | Anticuerpos anti-cd137 y metodos de uso de los mismos. |
CN116731179A (zh) * | 2017-06-25 | 2023-09-12 | 西雅图免疫公司 | 抗ror1抗体及其制备和使用方法 |
TWI820031B (zh) | 2017-07-11 | 2023-11-01 | 美商坎伯斯治療有限責任公司 | 結合人類cd137之促效劑抗體及其用途 |
BR112020001441A2 (pt) | 2017-08-01 | 2020-08-04 | Eli Lilly And Company | anticorpos anti-cd137 |
US11718679B2 (en) | 2017-10-31 | 2023-08-08 | Compass Therapeutics Llc | CD137 antibodies and PD-1 antagonists and uses thereof |
US11851497B2 (en) | 2017-11-20 | 2023-12-26 | Compass Therapeutics Llc | CD137 antibodies and tumor antigen-targeting antibodies and uses thereof |
WO2019109238A1 (fr) | 2017-12-05 | 2019-06-13 | Lyvgen Biopharma Co., Ltd. | Anticorps anti-cd137 et leurs utilisations |
AU2019208793A1 (en) | 2018-01-22 | 2020-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-4-1BB antibody, antigen-binding fragment thereof and medical use thereof |
AU2020276500A1 (en) | 2019-05-10 | 2021-12-16 | Lyvgen Biopharma Holdings Limited | Humanized anti-CD137 antibodies and uses thereof |
WO2021137230A1 (fr) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Procédés de culture de lymphocytes t et leurs utilisations |
WO2021137231A1 (fr) | 2019-12-31 | 2021-07-08 | Kahr Medical Ltd. | Procédés de culture de lymphocytes t avec un polypeptide de fusion 4-1bbl et leurs utilisations |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4257774A (en) * | 1979-07-16 | 1981-03-24 | Meloy Laboratories, Inc. | Intercalation inhibition assay for compounds that interact with DNA or RNA |
US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
US6303121B1 (en) | 1992-07-30 | 2001-10-16 | Advanced Research And Technology | Method of using human receptor protein 4-1BB |
WO1994026290A1 (fr) | 1993-05-07 | 1994-11-24 | Immunex Corporation | Cytokine denommee ligand 4-1bb et recepteur humain s'y fixant |
US7211259B1 (en) | 1993-05-07 | 2007-05-01 | Immunex Corporation | 4-1BB polypeptides and DNA encoding 4-1BB polypeptides |
ATE454449T1 (de) | 1993-09-16 | 2010-01-15 | Univ Indiana Res & Tech Corp | Menschlicher rezeptor h4-1bb |
AU5369996A (en) | 1995-03-23 | 1996-10-08 | Indiana University Foundation | Monoclonal antibody against human receptor protein 4-1bb and methods of its use for treatment of diseases |
DE69624436T2 (de) | 1995-04-08 | 2003-08-28 | Lg Chemical Ltd | Humaner 4-1bb spezifischer humaner antikörper und diesen produzierende zellinie |
US5874240A (en) | 1996-03-15 | 1999-02-23 | Human Genome Sciences, Inc. | Human 4-1BB receptor splicing variant |
EP0837141B1 (fr) * | 1996-10-03 | 2003-01-08 | Canon Kabushiki Kaisha | Procédé pour détecter un acide nucléique ciblé, procédé pour sa détermination quantitative et composés pyryliums pour l'analyse en chimioluminescence |
JP2001502325A (ja) * | 1996-10-11 | 2001-02-20 | ブリストル―マイヤーズ・スクイブ・カンパニー | 免疫調整の方法および組成物 |
WO1998036096A1 (fr) | 1997-02-14 | 1998-08-20 | E.I. Du Pont De Nemours And Company | Detection d'adn en double brin dans une solution homogene |
KR20000034847A (ko) | 1998-11-17 | 2000-06-26 | 성재갑 | 인간 4-1비비 분자에 대한 인간화 항체 및 이를 포함하는 약학조성물 |
US6734172B2 (en) * | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
WO2000041508A2 (fr) | 1999-01-15 | 2000-07-20 | Mount Sinai School Of Medicine Of The City University Of New York | Polytherapie contre le cancer s'effectuant par activation de molecules de co-stimulation exprimees par des cellules immunitaires et des cytokines |
US20020177551A1 (en) * | 2000-05-31 | 2002-11-28 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
ATE358718T1 (de) | 2000-02-25 | 2007-04-15 | Immunex Corp | Integrin antagonisten |
WO2002004009A2 (fr) * | 2000-07-12 | 2002-01-17 | Immunex Corporation | Methode de traitement du cancer |
PT1326961E (pt) * | 2000-09-15 | 2007-10-02 | Ortho Mcneil Pharm Inc | Composições e métodos para induzir respostas citolíticas específicas de células t |
US20040247563A1 (en) * | 2000-11-02 | 2004-12-09 | Lynch David H. | Method of enhancing lymphocyte-mediated immune responses |
AU2002246756A1 (en) * | 2000-12-26 | 2002-08-06 | Bristol-Myers Squibb Company | Use of combretastatin a4 and its prodrugs as an immune enhancing therapy |
WO2003006632A2 (fr) | 2001-07-12 | 2003-01-23 | Canvac | Methodes et compositions permettant de moduler la stimulation de lymphocytes t humaines in vitro et implications de cette modulation dans des strategies therapeutiques ex vivo et in vivo |
ES2328025T3 (es) * | 2001-10-09 | 2009-11-06 | Mayo Foundation For Medical Education And Research | Mejoramiento de las respuestas inmunitarias por anticuerpos agonistas 4-1 bb. |
US20030223989A1 (en) | 2002-04-18 | 2003-12-04 | Pluenneke John D. | CD137 agonists to treat patients with IgE-mediated conditions |
-
2002
- 2002-10-09 ES ES02802551T patent/ES2328025T3/es not_active Expired - Lifetime
- 2002-10-09 AT AT02802551T patent/ATE435655T1/de not_active IP Right Cessation
- 2002-10-09 DE DE60232895T patent/DE60232895D1/de not_active Expired - Lifetime
- 2002-10-09 US US10/492,056 patent/US7651686B2/en active Active
- 2002-10-09 EP EP02802551A patent/EP1434596B1/fr not_active Expired - Lifetime
- 2002-10-09 WO PCT/US2002/032364 patent/WO2003049755A1/fr not_active Application Discontinuation
- 2002-10-09 AU AU2002364935A patent/AU2002364935A1/en not_active Abandoned
-
2009
- 2009-11-06 US US12/614,150 patent/US8163550B2/en not_active Expired - Fee Related
-
2012
- 2012-03-21 US US13/426,151 patent/US8772026B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
US20120225043A1 (en) | 2012-09-06 |
EP1434596A4 (fr) | 2004-12-15 |
US7651686B2 (en) | 2010-01-26 |
US8163550B2 (en) | 2012-04-24 |
ATE435655T1 (de) | 2009-07-15 |
EP1434596A1 (fr) | 2004-07-07 |
US20050013811A1 (en) | 2005-01-20 |
US20100266611A1 (en) | 2010-10-21 |
WO2003049755A1 (fr) | 2003-06-19 |
ES2328025T3 (es) | 2009-11-06 |
US8772026B2 (en) | 2014-07-08 |
AU2002364935A1 (en) | 2003-06-23 |
DE60232895D1 (de) | 2009-08-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1434596B1 (fr) | Amelioration des reponses immunitaires par des anticorps agonistes liant 4-1bb | |
US7794710B2 (en) | Methods of enhancing T cell responsiveness | |
Clarke | The critical role of CD40/CD40L in the CD4-dependent generation of CD8+ T cell immunity | |
Klener et al. | Immunotherapy approaches in cancer treatment | |
EP3666888A2 (fr) | Méthode d'activation des cellules t pour le traitement du cancer | |
US9238064B2 (en) | Allogeneic cancer cell-based immunotherapy | |
CN111741764A (zh) | 使用细胞因子编码rna的治疗 | |
Coukos et al. | Immunotherapy for gynaecological malignancies | |
AU2016219379A1 (en) | Chlamydia-activated B cell platforms and methods thereof | |
CN114450296A (zh) | Il2激动剂 | |
CN113747913A (zh) | 涉及白介素-2(il2)和干扰素(ifn)的治疗 | |
CN113795272A (zh) | 涉及car工程化的t细胞和细胞因子的治疗 | |
Shimizu et al. | A single immunization with cellular vaccine confers dual protection against SARS‐CoV‐2 and cancer | |
EP3922642A1 (fr) | Procédé d'activation de lymphocytes t pour le traitement du cancer | |
Behboudi et al. | Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction | |
CN1440812A (zh) | 一种使用cd137结合激动剂增强免疫应答的方法 | |
Schütz et al. | MHC‐Ig induces memory T cell formation in vivo and inhibits tumour growth | |
CN113874389A (zh) | 用于特异性活化免疫效应细胞的白介素-2受体(il2r)和白介素-2(il2)变体 | |
Chung et al. | Co‐administration of CD40 agonistic antibody and antigen fails to overcome the induction of oral tolerance | |
US20220323493A1 (en) | Ex vivo antigen-presenting cells or activated cd-positive t cells for treatment of cancer | |
Fallatah | Combination of immune stimulatory strategies to promote anti-tumour immunity | |
Moynihan | Engineering immunity: Enhancing T Cell vaccines and combination immunotherapies for the treatment of cancer | |
KR20160127711A (ko) | 유비퀴티닐화 단백질 | |
de Castro | Antibody-based vaccines for delivery of antigen to dendritic cells in situ | |
Mansoor et al. | Genetically Modified T Cell Therapy Optimisation of the Chimeric T Cell Receptor for Cancer Therapy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20040424 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL LT LV MK RO SI |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20041102 |
|
17Q | First examination report despatched |
Effective date: 20050517 |
|
17Q | First examination report despatched |
Effective date: 20050517 |
|
RTI1 | Title (correction) |
Free format text: ENHANCEMENT OF IMMUNE RESPONSES BY AGONIST 4-1BB-ANTIBODIES |
|
GRAP | Despatch of communication of intention to grant a patent |
Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
|
GRAS | Grant fee paid |
Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
|
GRAA | (expected) grant |
Free format text: ORIGINAL CODE: 0009210 |
|
AK | Designated contracting states |
Kind code of ref document: B1 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LI LU MC NL PT SE SK TR |
|
REG | Reference to a national code |
Ref country code: GB Ref legal event code: FG4D |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: EP |
|
REG | Reference to a national code |
Ref country code: IE Ref legal event code: FG4D |
|
REF | Corresponds to: |
Ref document number: 60232895 Country of ref document: DE Date of ref document: 20090820 Kind code of ref document: P |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FG2A Ref document number: 2328025 Country of ref document: ES Kind code of ref document: T3 |
|
NLV1 | Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act | ||
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091008 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091109 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 |
|
PLBE | No opposition filed within time limit |
Free format text: ORIGINAL CODE: 0009261 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 Ref country code: MC Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 |
|
REG | Reference to a national code |
Ref country code: CH Ref legal event code: PL |
|
26N | No opposition filed |
Effective date: 20100409 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091009 Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20091009 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091031 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: FR Payment date: 20101105 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: DE Payment date: 20101027 Year of fee payment: 9 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: IT Payment date: 20101026 Year of fee payment: 9 Ref country code: GB Payment date: 20101025 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: LU Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20091009 |
|
PGFP | Annual fee paid to national office [announced via postgrant information from national office to epo] |
Ref country code: ES Payment date: 20101026 Year of fee payment: 9 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 |
|
GBPC | Gb: european patent ceased through non-payment of renewal fee |
Effective date: 20111009 |
|
REG | Reference to a national code |
Ref country code: FR Ref legal event code: ST Effective date: 20120629 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20120501 |
|
REG | Reference to a national code |
Ref country code: DE Ref legal event code: R119 Ref document number: 60232895 Country of ref document: DE Effective date: 20120501 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111009 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111102 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111009 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20090708 |
|
REG | Reference to a national code |
Ref country code: ES Ref legal event code: FD2A Effective date: 20130605 |
|
PG25 | Lapsed in a contracting state [announced via postgrant information from national office to epo] |
Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20111010 |